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Abstract 
-ucleosides and their analogs are considered a clinically proven class of 
therapeutic agents possessing anticancer and antiviral activity. Several trifluoromethyl­
substituted pyrazole -nucleosides (coded IA, I IA and I IA) and their nucleobases 
were synthesized and tested for the ability to induce apoptosis in acute human 
promyelocytic cell line (HL-60). The growth and proliferation of HL-60 was more 
effectively inhibited by NIA, I IA and their nucleobases compared to IlIA and its 
nucleobase. In addition D A fragmentation was detected in a concentration-dependent 
manner as a result of nucleosides treatment. A caspase-3-dependent apoptosis was 
observed based on the Western blot analysis of poly-ADP-ribose polymerase (PARP) and 
caspase-3. ucleosides and nucleobases also trigger the release of cytochrome-c from the 
mitochondria by disruption of mitochondrial membrane potential and ROS fOffi1ation. 
Furthermore, the use of zDEVD-frnk (caspase-3 inhibitor) and zLEHD-fmk (caspase-9 
inhibitor) resulted in an inhibition of the activity of caspase-3 and 9, accompined with no 
change in the activity of caspase-8 after the use of zIETD-fmk (casapse-8 inhibitor). 
These findings implicate the involvement of the caspase-9-dependent mitochondrial 
pathway. Treatment with nucleosides also resulted in a concentration-dependent 
upregulation and translocation of the proapoptotic molecule Bax, increased expression of 
other proapoptotic proteins Bad, Bak, decreased expression of antiapoptotic proteins (i.e. 
Bcl-2 and Bel-XL) and enhancement of p53 expression. Moreover, treatment with these 
agents resulted in accumulation of cells in the GO-G1 phase of the cell cycle, indicating 
the degradation of the cellular DNA. Interestingly, these nucleosides were found to 
posses anti-histone deacetyl transferase(s) (HDACs) potential, which is an exciting turn 
I I I  
in cancer therapy. This conclusion was based on the observed decease in the expressed 
le\el of HDAC- I. -2 and -3. Our results suggest that these novel synthetic nucleosides 
can induce apoptosis via the mitochondrial pathway, and therefore they could be 
considered as candidate anti-tumor agents. 
Key words: 1 llcleosides, Trifluoromethyl 
apoptosis, mitochondria. 
IV 
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Introduction and literature review 
1. I n t rod uction : 
I n the recent years cancer has become the ""orld's leadi ng health problem. In 
partIcular, there has been an increase of cancer incidence in the Gulf countries (I). 
Figures varY1l1g from one region to another depending on the specific  type of the 
cancer (II. Therefore, the growing need for qual ity cancer treatment through research 
has led to the establ ishment o f  various cancer therapy strategies and research centers 
in the world. 
Finding a cure or a remedy for cancer has become a chal lenge for all . The 
establ i  hed cancer therapies can delay the spread o f  the cancer or in some cases 
destroy it completely. The outcome depends on the detection of this i l lness in i ts early 
stages, and also on the genet ic susceptibil ity of the patients, meaning that some genes 
may be in regions o f  chromosomes which are more susceptible to genetic 
damage, change or may contain sequences which are more l ikely to be altered by 
spontaneous mutations. Therefore, i t  could be stated that cancer is  a genetic disease in 
\\'hich an uncontro l lable cel l  division takes place, resul t ing in the dismption of the 
homeostasis between cel l  pro l i feration and cell death (2) 
The term chemotherapy refers to the use o f  a wide range o f  dmgs that work by 
ki l l ing dividing cells .  S ince cancer cel ls have lost most o f  the regulatory functions 
present in  normal cel ls ,  they wi l l  continue to divide when other cells do not (2) This 
feature makes cancer cells more susceptible to cytotoxic agents. The 
chemotherapeutic agents are e ither natural ly occurring compounds that have been 
identi fied in various p lants or synthetic chemicals (2). They can cause cell death in a 
variety o f  ways, and some o f  these chemotherapeutic dmgs have been briefly 
described below (2) . 
1 )  Antimetabol i tes: D rugs that interfere with the formation of key 
biomolecules within the cell  such as nuc leosides, which are part o f  the bui lding 
blocks o f  O:\A (nucleotides) . These drugs ultimately interfere with Dl A replication 
and therefore cell division. 
2) Genotox ic Drugs : Drugs that damage D A. By causing D1 A damage, 
these agents interfere with DNA repl ication, and normal process o f  cel l  division. 
3) Spindle lnl1ibitors : which prevent proper cel l  division by interfering with 
the cytoskeletal components that enable one cell to divide into h o.  
�) Other Chemotherapy Agents : These agents inhibit cel l  division by 
mechanisms that are not covered in the three categories l isted above. 
1 u leosides and their analogues, which belong to the first category, are 
considered a c l inical ly proven class o f  chemotherapeutic agents possessing anticancer 
and ant iviral act iv i ty (3). The effectiveness of this class o f  chemotherapeutic agents or 
their mode o f  act ion (tox icity) results from their abi l i ty to cause covalent 
modification of D A. Thus, they become i ncorporated into the genetic material 
during D A repl ication and destroy it by preventing the fidel i ty of repair systems 
within the Dl A (3), which in tum results in the death o f  the cel l  (apoptosis). In other 
words they act as antimetabolites by competing with the natural physiological 
nuc1eosides within the body (3) . 
There are several classes of nucleosides, the most important of  which are the 
f luorinated compounds containing trifluoromethyl group (CF3) . These compounds 
have several medical appl ications, as they act as anti viral , antifungal and 
antiin£1amatory agents (4). The presence of trifluoromethyl groups (CF3) results in 
alteration of the chemical and pharmaceutical properties, for example increasing their 
cytotoxic effect within the cel ls (4), due to the presence o f the fluorine. 
Apoptosis or grogrammed fel l  Qeath (PCD) is  a natural mechanism m the 
body to maintain its integrity and functionality by destroying non-desirable and 
2 
hannful cells (2). Most physiological cell death proceeds by apoptosis, which ensure 
cell remo\al without affecting neighboring cells or causing an inflammation. 
3 
1 .  Ba ic m e d ical che m i  try o f  n u cleo id e : 
Chemical analogues of nucleosides have been frequent subjects of research in 
medIcinal chemistry due to their marked activity in several fields of therapy including 
anticancer and antiviral analogues (3).  They also might act as cytotoxic compounds or 
immunosuppressive drugs (3) .  The cytoto ic class comprises the anti-cancer 
nucleosides, which are antimetabolites that inhibit the synthesis of nucleic acids (3 , 5). 
As they are h drophilic (water- loving) compounds, they require special transporter 
proteins to enter the cells. Once inside the cells they are activated to become 
triphosphate derivatives, which can incorporate within the D A or RNA and damage 
them by interfering with the enzymes responsible for their synthesis such as the 
polymerases. This results in damaging of the genetic component of the cell and 
eventually leading to apoptosis (3, 5,6) . 
Natural nucleosides and their synthetic models are considered one of the most 
important metabolites of the cell (3). The nucleosides found in cells are deri atives of 
the heterocyclic, highly basic compounds such as purine and pyrimidine. Their 
chemical basicity (alkalinity) has given them the common term "bases". There are 
five major nucleobases found within the cells (see Fig.I.I), that primarily function as 
the building blocks of the genetic material, commonly referred to as D A and RNA. 
ucleoside analogues are synthetic compounds that are structurally similar to 
natural nucleosides. Each of these are small molecules that effectively target several 
enzymes such as kinases and polymerases (3). Naturally occurring nucleosides are 
modified in cells to generate derivatives, termed nucleotides that are utilized by 
polymerases as the basic building blocks of DNA and RNA genetic material. 
ucleosides also have other physiological roles in processes such as coronary 
blood flow, myocardial O2 balance, inflammation and neurotransmission (5). 
ucleosides are either derived from the diet or produced by tissues through de novo 
4 
bios)-l1thellC pathways (:.7\. Cells deficient in de novo biosynthetic pathways are 
dependent on salvage pathways of nucleosides [Tom the extracellular environment 
\\ hlCh includes cells such as erythrocytes, leukocytes, bone marrow cells, some brain 






Cyto ine Thymine Uracil 
Pyrimidines 
Fig. 1. 1 : Major nuc1eobases found in the cells: Purine analogues include guanine (G) and adenine (A), 
Pyrimidine analogues i nclude cytosi ne (C), thymine (T) (found in D A), and urac il (U) (found in the 
� A). 
1.1. Chemical structure of the physiological nucleosides: 
The main idea behind the concept of synthetic nucleoside analogues is their 
ability to compete with the natural ones. In order to understand their mechanism of 
action, a brief overview of the physiologically important nuc1eosides is discussed 
below. When a sugar bonds together with a nitrogenous base, which are two of the 
three components of the building blocks of nucleic acids (nuc1eotides), a structure 
5 
known as a "0 ucleo ide" is generated. There are five n itrogenous bases that are found 
in D);A and Rl A (although uraci l  is found OL LY in RNA). These five bases are 
divided into t\.vo categories' purine and pyrimidine based upon their molecular 
structure. The dem'atives of purin are called aden ine (A) and guanine (G), and the 
derivat ives of pyrimidine are cal l d thymine (T), cytosine (C) and uraci l  (U) (see 
F· I '1) ( ) 1 9 . . .:. . 
Pho pha te� 
group 
o II 5' 




\------� �----�) y 
Nucleoside 
�------ ------) y 
Nucleotide 
Nucleoside = sugar + base 
Nucleotide = nucleoside + phosphate 
H 
J7XC�1 \ 9 l�CH � N 
Purine 
Pyrimidine 
Fig. 1 .2: Schematlc v iew of the nucleoside structure. itrogen bases with either purine or pyrimidine 
nngs that are associated with pentose sugar mOieties are called nucleosides. If a phosphate group is 
attached to the nucleosldes i t  forms a nucleotide. 
The pyrimidine ring system is planar whereas the purine rings have some 
pucker. The plai n  b ases have low solub i l i ty, but their  nuc leoside form has higher 
solub i l i ty due to the addit ional polar groups (7). Purines and pyrimidines can undergo a 
keto-enol tautomeric shi ft .  The keto tautomer i s  cal led a l actam ring, and i s  the 
6 
predominant form at neutral pH til. The nucleosides are coupled either to D-nbose or 
to 2'-deoxy-D-ribo 'e through a �- '-glycosidic bond between the anomeric carbon of 
the ribose and the 9 of a purine or 1 of a pyrimidine. That is why nucleosides are 
mtrogen bases either with purine or pyrimidine rings that are associated with sugar 
moieties, \\ hile nucleotides are nucleosides that are bound to a phosphate group n. 
1 . 1 . 1 .  .Mode of a c tion of n u cleosides: 
In order to understand the antimetabolitic action of nuc1eosides it is necessary 
to briefly discuss the processes that are targeted by these agents. The term metabolism 
refers to the complex chemical reactions that take place in the body (8). A metabolite is 
a general tenn for the organic compounds that are synthesized, recycled, or broken 
down in cells (8). The materials that provide the key metabolites enter the body as 
food. These compounds can be degraded into simpler structures that can be re-used in 
our cells. Examples of such simple structures include vitamins and amino acids. 
Metabolites that are the end-products of a process or pathway may be excreted from 
the body. An example is urea, the end-product of protein metabolism, excreted from 
the body as a component of urine. 
Antimetabolites are structurally similar to metabolites, but they cannot be used 
by the body in a productive manner (8). In the cell, antimetabolites are not 
distinguished from the metabolites they resemble, and are processed within the cell in 
a manner analoguous to the nonnal compounds. The presence of the 'decoy' 
antimetabolites prevents the cells from carrying out vital functions and the cells are 
unable to grow and survive (22). uc1eoside analogues therefore are molecules that are 
chemically modified versions of one of the natural nucleosides. Mimicking the role of 
natural nucleosides, therapeutic nucleoside drugs are generally incorporated by 
7 
endogenous pol;merases (3,22) and this e\'ent impairs either the s}TIthesis or the 
functionality of the resultant genome and therefore suppresses repl ication (8), Many of  
the antimetabol i tes used in  the treatment o f  cancer interfere with the production of  the 
nuc leic acids, RNA and D 
divide, 
, If new D A cannot be made, cells are unable to 
1 . 1 .2 .  Tra n po rta tio n a nd bioavailability of nu cleosides: 
ucleosides are involved in signal ing in a number o f  physio logic systems (9,10), 
Plasma membrane transport of  nucleosides is mediated by equ i librative and 
concentrative nuc leoside transporters, which may have specificity for purines or 
pyrimidines (11), The two fami l ies, equi l ibrative and concentrative, differ in  their 
mode of transport, substrate selectivity, and sensit ivity to i nhibitors (9-11), Equi l ibrat ive 
transporters mediate the influx and efflux of both purine and pyrmidine nucleosides 
down a concentrat ion gradient (10) , The second fami l y  o f  nucleoside transporters 
mediates the sodium-dependent, concentrative uptake o f  nuc1eosides (10), These 
transporters are driven by an electrochemical ion gradient and under physiological 
conditions mediate only the influx of  nucleoside analogues ( 1 0) , In mammalian cel ls 
nucleosides are transported through the membrane by both equi l ibrative and Na+­
dependent (concentrative) nuc leoside transporters, S uccessfu l  transport o f  the 
nucleosides through the membrane direct the ce l lu lar uptake o f  many therapeutic 
n uc leosides used in the treatment of cancer, viral infections and cardiac arrhythmias 
(9-11), This mean that the efficient transportation and delivery of the nucleoside into the 
cel l  contribute indirectly to its cytotoxicity and therefore its therapeutic potential, 
which indicates that the better the transportation the more potential the nucleoside 
may exert, Nucleoside transportation i s  also vital for nucleotide synthesis by the 
8 
salvage path\\ ays ( nucleotide syTIthesis by other cel ls such as brain cells) .  Several 
human nuc leoside transporters have been ident i fi ed, c loned, and characterized (3 ). 
There is emerging evidence that the abundance and tissue distribution of nucleoside 
transport proteins contributes, in part, to the cel lular spec i fici ty of and sensi tivity to 
nucleoside analogues (9. 1 0) . However each of these compounds also possesses unique 
drug-target interactions that help explain their di fferences in  activi ty in various 
diseases. For example, the cytotoxic effects of  the purine analogue Fludarabine (a 
chemotherapeutic agent) on quiescent cells may be explained by interaction with 
targets involving DNA repair rather than repl ication combined with direct or indirect 
effects on mitochondria (10. 1 1) . The biological ly act ive fonn o f  most purine or 
pyr imidine analogues i s  the nucleoside 5'-mono, di- or triphosphate (phosphorylated 
fOffi1) ( 1 0) . However, the nuc leoside (unphoshorylated fonn) is admi nistered most 
o ften, because of the ease with which it penetrates cel ls  by fac i l itated transport, 
special ly in the case o f  cancer and H IV treatments ( 1 2,13) . Tumor cells and viral ly 
infected cel ls  are often more penneable to nucleosides and their analogues than 
normal cel ls,  which could provide a therapeutic advantage p,II, 1 3, 1 4) . A drawback o f  
this i s  that many nucleoside derivatives fai l  t o  exhibit s ign ificant antiviral or 
anti tumor act ivi ty because they are not phosphorylated by cel lu lar enzymes to the 
active nucleotide form (3, 1 0) . 
Thus modulating nuc leoside transport processes has been proposed as a means 
of enhancing the efficacy of the nuc leoside analogues (9
,[0) . Pharmacologic i nhibitors 
of transporters are available such as hENTI and hENT2 , and they are capable of 
protecting bone marrow progenitors from the cytotoxic e ffects of  nuc leoside 
analogues (disruption of replication and cel l cycle processes) (ll). However, the degree 
to which transport inhibitors might also protect mal ignant cel ls is unknown, although 
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inhibitor-insensitive nucleoside transporters ha\ e been identified in cul tured cancer 
cel ls  (II). The cel lu lar regu lation of nuc leoside transport is now an area of intensive 
study, and has the potential to al lo\-\ selective upregulation of nucleosides analogues 
uptake in malignant c lones. For example· in acute promyelocytic cel l  l ine (HL-60) the 
pathways involved in the regulation of nucleoside transporters depend on 
di fferentiation status (e.g .  granulocytic or monocytic),  and this may provide insights 
into new approaches to modulate the uptake of anticancer nuc leosides and increase 
the efficacy o f  these drugs in leukemias (3, 1 0, 1 1 ) . There could be considerable 
therapeutic potential for nuc leoside analogues that can penetrate the tumor cel l  
membranes and that are resi stant to enzymatic hydrolysis and can be incorporated into 
Dl A or RNA. 
1.2. Puri ne and pyrimidine analogues: 
There are several di fferent cel lular targets for antimetabol ites. Some common 
c lasses of antimetabol i tes are: 
• Pyrimidine Antagonists 
• P urine Antagonists 
The pyrimidine and purine antagonists act to block the synthesis of pyrimidine 
and purine contain ing nuc leotides. The drugs used to block the construction of these 
nucleotides have structures that are similar to the natural compounds. They may exert 
their effects at di fferent steps in a pathway and may directly inhibit crucial enzymes. 
These antagonists function by inhibiting DNA synthesis i n  two different ways: 1) 
They can compete with the production o f  the natural pyrimidine and purine containing 
nucleosides ( 1 1 ,16, 1 7) . I f  a cell does not have suffic ient amounts o f  them, the DNA 
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sy11thesis is halted and the cell cannot di\ ide (10, 1 1 ) , 2) The antimetabolites may be 
mcorporated into a growing D A chain and lead to termination of the chain 
elongation process (3.8,15), Thus the presence of the inhibitor (nucleoside analogue) is 
thought to interfere \vith further cell division ( 1 0, 1 1
, 1 4, 1 8) . Example of pyrimidine 
nucleosides are Cytarabin (ara-C) and Gemcitabine, \ hereas the most common 
purine nucleosides are Fludrabine and Cladribine (see Fig.I.3) (3,8). 
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Fig.1.3: Pynnudine and purine analogues used in chemotherapy. Cytarabin (ara-C) and Gemcitabin are 
pynmidine analogues, whereas F ludrabine and Cladribine are purine analogues, 
1,2.1, Thera peutic roles of purine and pyrimidine a na logues: 
The cellular specificity of and sensitivity to the nucleosides depends on the 
abundance of their distribution in the tissues (3,5), and their use in treatment is due to 
the unique drug-target interactions (3). For example, purine analogues can be used in 
the treatment of neurotoxicity, vomiting, septicemia (blood poisoning), and HIV 
therapy, whereas pyrimidine analogues are used as a cure for diarrhea, hand-foot 
syndrome, and some leukemia cases (3). 
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Cytarabine or Arabinosylcytosine (Cytosar-UK, ara-C) is an anbmetabolite 
that acts as a pyrimidine antagonist (3 , 1 9.20). It is  thought that its act ivi ty is  primari ly by 
interrupting D A synthesis .  Malignancies for which Cytarabine is used include acute 
non- lymphocytic leukemia, acute lymphocytic leukemia and chronic myelocytic 
leukemia. Cytarabine is administered as an infusion or as an injection under the skin. 
Common side effects inc lude bone marrow suppression, anorex ia, and oral/anal 
inflammation or ulceration (3 ,2 1 ) . Because cytarabine is a suppressor of bone marrow 
activity, it is important to perform blood tests to monitor b lood ce l l  and platelet counts 
during the treatment (3,18). On the other hand, Gemcitabine is e ffective against a wide 
range of solid tumors and it is a potent radiation sensitizer (3, 1 5) , as well as a good 
substrate for nucleoside transporters (3). Cornmon side effects inc lude:  bone marrow 
suppression , weakness , fever , nausea and vomiting. It is suggested that the toxic 
effect o f  this analogue (radiosensitization) depends on perturb ing nucleotide pools 
producing misrepair  after radiation (22) . Previous studies tried to determine whether 
Gemcitabine-mediated radiosensit ization induced apoptosis, and they have found that 
apoptosis in Gemcitab ine-mediated rediosensi t ization i sdependent upon the cel l  l ine 
used and the dose administered (22) . However their i nvestigation was l imi ted to the late 
apoptotic events (caspase-3 activation and morphological changes) (22) . 
F ludarabine leads to tennination of the chain elongation process mediated by 
DNA polymerase by incorporating into the DNA (3,2 1 ) . I t  also can impair DNA 
rep l ication by inhibi ti ng ribonuc leotide reductase (23). It is suggested that this analogue 
can i nduce apoptosis via activation of caspase-3 and -9 (2 1 ) . F ludarabine is  used to 
treat chronic B-cel l  lymphocytic leukemia and is administered as an inj ection. 
Adverse effects are s imi lar to Gemci tabine. ucleoside analogues in  general can 
cause several side effects. Frequent complaints inc lude fat igue, headache and a 
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variety o f  gastrointestinal problems such as abdominal discomfort, nausea, vomiting 
and dIarrhea (3) . They are el iminated mainly by renal excret ion and do not interact 
with drugs that are metabol ized by hepatic enzymes , therefore they wi l l  not be 
destroyed before reaching their targets by the detoxifying action o f  the l iver (3) . 
1 .3 .  yn the is of t rifluoromethyl-n u cleosides: 
A \\ ide range o f  trifluoromethyl-therapeutic agents exhibit a variety of 
biochemical properties (3) The introduction of fluorine in general and trifluoromethyl 
groups into organic compounds al lows modification of their chemical, physical, and 
pharrnaceutical properties (4.24) . The preparation o f  fluorine heterocycles is well 
documented . There are two general protocols (4,24): 1 )  fluorination of an exist ing 
heterocycl ic  nng including functional group transfom1ation, for example 
transformation of a carboxy moiety to a tri fluoromethyl group and 2) 
trifluoromethylation of heterocycles by means of tri£luoroacetonitri leoxide or 
trifluoroacylketenes. The disadvantage of these methods i s  that they might be 
dangerous during the preparation, because the reagents used are highly toxic .  
Therefore new approaches have been developed for the synthesi s  of  
trifluoromethylated (CF3) heterocyc l ic compounds (4) . However the search for new 
reagents and methods for the synthesis of CF3-contain ing compounds is sti l l  a quest i n  
orgaruc synthesis .  One simple and useful approach t o  the syntheses of  
trifluoromethyl-contai ning heterocycles i s  a synthesis based on  the uti l ization o f  
unsaturated ketones with a tri fluoromethyl group (24) . Trifluoromethyl-I ,3-dicarbonyl 
compounds have been proven to be versat i le bui lding b locks for a wide variety o f  
tri fluoromethyl-substituted heterocyles. These include pyrazoles, isoxazoles thiazoles, 
pyridines, pyrimidines and pyrones (4). 
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1 .3 . 1 .  The po t e n tia l of triO u o rom ethyl-n ucleo ide in m edici n e: 
Fluorinated molecules particularly fluorinated heterocyc les are the focus of much 
interest In modem medicinal chemistry because they exhibit a wide range of 
biological effects t4) .  For example, tri Ouoromethyl-substi tuted compounds ha e been 
reported to possess bio logical act ivi t ies such as herbic ides, fungic ides and inhibitors 
of the platelet aggregation (4). Recently, much attention has been focused on pyrazoles 
as antiviral and anticancer agents after the discovery of the pyrazole C-glycoside 
pyrazo furin, s ince they were used as tools for studying confonnational requirements 
of o l igonucl otides to enhance the understanding of biochemical pathways/processes 
and the development of therapeutic agents (e.g. antisense and ant i  viral) (4) .  
ucleosides are becoming an increasingly important c lass of  agents in the 
development, scale-up, and manufacture of new biotherapeutics. 
2 .  ucleosides a nd cancer: 
Despite promising leads in  the search for new chemotherapeutic agents there 
remains an urgent need to develop more effective and less tox ic  drugs. Nucleosides 
and their corresponding nuc leobases are the fundamental bui lding blocks of many 
b io logical systems and as a result, synthetic analogues have been investigated due to 
their inherent structural resemblance to the natural ly occurring nucleosides and 
nucl eobases. Due to this intertwined relationship between physiologic and synthetic 
nucleosides, they (the synthetic analogues) could be used as a chemotherapeutic 
approach to treating cancer. Most chemotherapeutic nucleosides have been used in 
leukemia treatment (3. -). 
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2 . 1 .  N a t u re o f  l e u kemia a nd pos ible diagno i : 
Leukemia is a blood cancer in which b lood cel ls  mature abnormally or 
incompletely (25). These abnormal or immature cel ls  accumulate in the body, and are 
unable to carry out the functions of normal blood cel ls  (2:, 16) . Since leukemic cells are 
abnormaL they cannot function properly; for example. they cannot help the body fight 
infections (25) .  For this reason, people \ ith leukemia often get infections and have 
fevers. Also, people  with leukemia often have less than the normal amount of healthy 
red blood cel ls and platelets. As a result there are not enough red blood cel ls to carry 
oxygen through the body. With thi s condition, cal l ed anemia, patients may look pale 
and feel weak and t ired . When there are not enough p latelets, patients b leed and 
bruise eas i ly (2o,Y'). ormal b lood contains three major groups of ce l ls :  white b lood 
cel ls, red b lood cel ls, and platelets. All three types develop from one immahlre cel l 
type cal led stem cel ls  in a process cal led hematopoiesis (27) . Leukemia is c lassified by 
how quickly i t  progresses . Acute leukemia is  fast-growing and can overrun the body 
within a few weeks or months (26). By contrast, chronic leukemia is slow-growing and 
progressively worsens over years (25). The blood-forming (hematopoietic) cel ls  of 
acute leukemia remain in an i mmature state, so they reproduce and accumulate very 
rap idly (25-27), Therefore, acute leukemia needs to be treated i mmediately, otherwise 
the disease may be fatal within a few months (16,:?7) . On the other hand, in chronic 
leukemia, the b lood-forming cells eventual ly  mature, or differentiate, but they are not 
normal,  as they remain i n  the b loodstream much longer than normal white b lood cel ls,  
and they are unab le  to combat infection well (
2-2 7)
. Moreover leukemia also is  
c lassi fied according to the type of  white b lood cel l  that is  mult iplying - that is,  
lymphocytes ( immune system cells), granulocytes (bacteri a-destroying cells),  or 
monocytes (macrophage-forming cells) (27). I f  the abnormal white blood cel ls  are 
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primari ly granuloc;tes or monocytes, the leukemia is categorized as myelogenous, or 
I ' d  I k . \�6 17) . myc 0 1  , eu cmIa � - . On the other hand I f  the abnom1al b lood cel ls arise from 
bone marro\v lymphocytes, the cancer is cal led lymphocytic leukemia (25) .  There are 
over a dozen different types of  leukemia, but four types occur most frequently. These 
c lassifications are based upon whether the leukemia is acute versus chronic and 
myelogenous versus lympho ytic ,  that i s  (25-27) :  
• Acute lymphocytic leukemia (ALL):  ALL - also known as acute 
lymphoblastic leukemia - is a malignant disease caused by the abnormal 
growth and development of early nongranular white b lood cel ls, or 
lymphocytes (25) .  
• Chronic lymphocytic leukemia (CLL) :  CLL i s  thought to result from the 
gradual accumulation of mature, long-l ived lymphocytes (25) . Therefore, this 
cancer is  caused not so much by overgrowth as i t  is  by  the extreme longevity 
and bui ld-up of mal ignant cells (25.26) . Although the rate of  accumulation 
v aries among i ndividuals, the extensive tumor burden eventual ly  causes 
complications in all CLL patients (27) . 
• Acute myelogenous (granulocytic) leukemia (AML):  AML begins with 
abnormaliti es in  the bone marrow b last cel l s  that develop to form 
granulocytes, the white b lood cel ls that contain small partic les, or granules 
(25-2'7). The AML blasts do not mature, and they become too numerous in the 
blood and bone marrow (25) .  
• Chronic myelogenous (granulocytic) leukemia (CML):  CML i s  known as a 
myelopro l i ferative disorder - that is, it is a disease in  which bone marrow 
cel ls  prol iferate (mult ip ly) outside of  the bone marrow tissue 
(26,27) . 
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2 . 1 . 1 .  A n ti- leu ke mic analog u e : 
Treatment o f  leukemia continues to ad ance .  Improved understanding of the 
basic di sease process as \vel l  as the avai lab i l i ty of better drugs and supportive care are 
leading to more remissions. Treatment i s  divided into two categories:  1 )  upportive, 
including b lood transfusions to rel ieve the anemi a, platelet transfusions to help 
prevent b leeding and antibiotics to control infections ( 1 5 , 15-27) . 2)  Chemotherapy 
treatment \ i th chemical drugs ( 1 7, 25-27) such as Ara-C, which is one of the oldest 
chemotherapy drugs that has been commonly used in treatment of acute myeloid 
leukemia, chronic myeloid leukemia, acute lymphoid leukemia, and lymphomas ( 1 ,23) . 
As drugs, nuc leoside analogues generally offer high selectivity, excel lent potency, 
long duration of action and potential for relatively straightforward scale-up and 
manufacture (3) . As a result, nuc leoside and nucleoside analogues are particularly 
well-suited for the extended treatment of such maladies. 
3.  M echanism(s) of anti-cancer effect of synthetic nucleosides: 
Several decades of genetic and molecular study have revealed enormous 
insights into the mechanistic underp innings of cancer (2, 1 8). From the identi fication of  
dominantly acti ng oncogenes to  the signaling pathways which modulate the cel l cycle, 
our understanding o f  the machinery o f  ce l l  cyc le progression as wel l  as the regulatory 
circuits which control it  have never been so detai l ed 
( 1 2, 1 8)
. However the translation of 
these discoveries into improved therapeutic approaches has been s low. Therefore 
understanding the mechanism of action of the anti-tumorgenic effects of these 
analo gues is vital for the prospect of unraveling therapeutic strategies for cancer. The 
c urrent understanding of how nucleoside analogues exert their  anti -cancer potential i s  
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that, i f  they destroy cancerous celis,  they are achieving this either by the process of  
programmed ce l l  ueath or the di sruption of ce l l  cyc le  progression. 
3. 1 .  N u cleo ide and apopto is: 
Recent investigations indicate that widely used chemotherapeutic agents 
induce apoptosis in suscept ible cel ls (28,29). For example treatment with the 
topoisomerase I I  inhibitor, Etoposide results in morphological and b iochemical 
evidence of apoptosis in  a variety of  cel l  types (18). The events occurring between 
stabi l ization of topoisomerase I I-D A complexes and init iation of apoptosis are 
unc lear but subsequent events in al l  of  these cel l  types include c leavage of DNA(29- 3 1 )  
and activation o f  a family o f  proteins known as 0steine-dependent �artate-directed 
proteases (32) cal led caspases . 
3. 1 . 1 .  D efinition of apoptosis: 
Apoptosis, or programmed cel l  death (peD), i s  a normal process in  the 
de elopment and health o f  multicel lular organisms (2,32,33). It occurs in response to a 
variety of stimuli (33) . Apoptosis is dist inct from another form of  cel l  death cal led 
necrosis in which uncontro l led cell  death leads to lysis of cells fol lowed by 
inflammatory responses that can potential ly lead to serious health problems 
(33) . 
During apoptosis caspases are activated in a cascade-fashion, eventual ly leading to the 
activation of the "effector caspases", such as caspase-3 and caspase-6. These caspases 
are responsible for the destruction of the key cel lular proteins such as DNA repair 
enzymes that leads to the typical morphological changes observed in cells undergoing 
apoptosis (33 .34). 
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3. 1 .2 .  A poptotic pathn ay : 
There are several mechanisms through which apoptosis can be induced (see 
FigJ.4) .  The preference of one mechanism over another depends on a number of 
fa tor such as the type and the strength of the stimulus, the expression of pro- and 
anti-apoptotic proteins (e .g. the Bc l-2 proteins or the Inhibitor of  Apoptosis Eroteins 
(I P )) . and th stage of the cel l cycle (35-37 ) .  
"I nt  r i  ns ic " "Ext ri n si C" 
Fa ::: l igan d 
klti - Fa ::: ;<;, 
TN F Q'. 
DNA damage (e � .  etop osid e ,  Iddi ation)  
P KC n hibrtion (e .g . staurosporin e)  
C as p as e 8 \ C�O Ch ro m e c 
C as p as e g 
P ro- cas p as e  3 �K 
(in a ctill e) � 
C as p as es 5,7 
C l eave d cas p as e  3 1---... � (a ctille) lAPs 
� 
D e ath s u bstrates 
Fig. I A :  Schematic representation of the apoptotic pathways, featuring the main markers invo lved in 
each pathway: Intrinsic pathway (m itochondrial pathway), and extrinsic pathway (death-receptor 
pathway). 
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In some cases apoptosis IS initiated fo l lo\ving intrinsic signals that are 
d d ·  I I  1 (3·1.38) C pro uce In response to ce u ar stress . e l lu lar stress may occur from exposure 
to radiation or chemicals or to viral infections. In other cases, the apoptotic stimul i  
comprise extrinsic s ignals such a s  the binding of death inducing l igands to c e l l  surface 
receptors (39). The latter occurs for example when T -cel ls recognize damaged or virus 
infected cel ls  and initiate apoptosis in order to prevent damaged cel ls  from becoming 
neoplastic (cancerous) or virus-infected cel ls  from spreading the infect ion (39). 
3. 1 .2 . 1 .  M itochondrial pathway: 
l i tochondria have the abi l ity to promote apoptosis through the release of 
cytochrome c (Cyt c) which together with �poptotic Q.rotease-�ctivating factor-
l CApaf- l )  and ATP forms a complex with pro-caspase-9 (40). Formation of this 
complex leads to the activation of caspase-9 and subsequent induction of apoptosis 
(40). The factors responsible for the release of Cyt c from the mitochondria are sti l l  
completely not understood. Anti-apoptotic members of  the Bc l-2 fami ly of proteins, 
such as Bcl-2 and Bcl-XL, are located in the outer mitochondrial membrane and act to 
promote ce l l  survival (34,.tO). On the other hand pro-apoptotic members of the Bcl-2 
fami ly, such as Bad and B ax, also mediate their effects though the mitochondria, 
either by interacting with Bel-2 and Bel-XL, or through direct interactions with the 
mitochondrial membrane (34,40,4 1 ). It has been suggested that Bax can form a 
transmembrane pore across the outer mitochondrial membrane, leading to loss of  
. I ffl f C d ' 
. 
d . c: CAIF)  (34, 40,4 1 )  membrane potentIa and e ux 0 yt c an �poptOSlS 1n  ucmg !.actor . 
It i s  thought that Bc l -2 and Bel-XL act to prevent this pore formation and that 
heterodimerization of Bax or Bad with Bel-2 or Bcl-XL inhibi ts their protective effects 
(40�2) 
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3. 1 .2 .2 .  Receptor m ed iated pa thw ay: 
Death receptors are cell surface receptors that induce apoptosis triggered by 
the bindIng of speci fic l igands (39) . Death receptors belong to the tumor necrosis factor 
(TNF) gene superfami ly and generally can have several functions other than init iat ing 
apoptosis (39). The best characterized of the death receptors are CD95 (Fas), TNFR I  
(TNF receptor- I )  and the TRAIL ( I  F -related £!poptosis induci ng ligand) receptors 
DR-l and DRS (34.39) . These receptors can mediate apoptosis by activation of caspase-
8, which in turn activates caspase-3 ,  and leads to apoptosis (39) (Fig. 1 .4) .  However 
apoptot ic programs cannot simply be described as two paral lel programs converging 
on a common caspase machinery. First, genetic studies " ith caspase-defic ient mice 
demonstrate that the requirement for different death effector molecules during 
apoptosis is highly variable, being cel l-type and stimulus spec ific  (43,44) . Second, a 
l arge degree of ' c ross-talk' exi sts between pathways. For example, p53 can 
transactivate genes encoding death receptors (44). Deficiencies in regulation of 
apoptosi s  contribute to wel l-known pathologies, such as autoimmune diseases, cancer, 
and viral infections (45) .  
3.1.3. A poptosis and ca ncer thera py: 
Several anticancer agents such as daunorubic in (DAU), may init iate apoptosis 
at low concentrations to k i l l  tumor cells (46,47). Those cel ls  become damaged 
irreversibly and exhibit b iochemical and morphological changes i ncluding 
mitochondrial alteration cytoplasmic and nuclear condensation, and DNA 
degradation into ol igonucleosomal fragments (46) The various apoptotic signals 
induced by different anticancer drugs through di fferent mechanisms may converge on 
mitochondria result ing in the release of apoptogenic factors and activate caspase 
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cascade that is involved in the release of  Cyt c from mitochondria (.34 .I"). E ffector 
caspases, including caspase-3 may be activated via mitochondria-dependent or -
independent path\,,rays t3.J..J8) .  One of the current theories exploring the release of Cyt c 
suggests the invoivement of pores within the mitochondrial outer membrane formed 
by proapoptotic m mbers or the Bcl-2 family (e .g .  B id. Bax. and Bad) (3.1). These 
mechanisms mediate the passage of unbound Cyt c through the mitochondrial outer 
membrane. However, the mechanism by which Cyt c dissociates from the i nner 
membrane is  less understood (34). 
The process by which cancer spreads from a pnmary to a secondary site 
(metastasis) is the major cause of concern in cancer. This process in induced when 
very few cel ls leave the primary tumor to give rise to secondary tumors (49). Metastatic 
cel ls  are subj ected to various apoptoti c  stimuli and in order for the process to 
succeed these cel ls which undergo various genetic changes, must decrease their 
sensit ivity to apoptotic stimul i  (.19). Therefore, i f  the resistance to apoptotic stimuli 
could be abol ished, or in  other words the apoptotic sensitivity could be increased, and 
the effective weapon against metastatic cancer would be unleashed. 
3.2 .  Nucleosides, the cell cycle and chromatin mod ification ; a quest for a 
con n  ection: 
Pro l i feration and programmed ce l l  death (apoptosis) exert a concerted action 
m model ing the organi sm during normal development and in maintaining tissue 
homeostasis l2, 1 2,2 1 ) . Both cel l  cyc le  progression and apoptosis biochemistry and 
molecular biology have been widely studied and characterized during the last ten 
years. ow, it is evident that each cel l  is able  to integrate both extra- and intracellular 
survival and death signals thereby control l ing its own growth rate or, when harmful  
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signals prevai l ,  induc ing its self-destruction 
( 1 2 .2 1 )
. This is achieved mainly because of 
multiple interaction� with the pS3 pathway. which guards against genomic instabil ity 
by inducing both arrest of the cel l cycle and apoptosis (:2 1 ,30) . The p53 hlmor 
suppressor is also activated by phosphorylation and acetylation and interacts 
physlcal lY 'vvith histon s!eacetytransferase§. (HDACs) (50). A growing body of l iterature 
has establ ished the role of H DACs in chromatin remodeling and gene expression. 
Furthermore, HDAC inhibition selectively alters the activity and expression of cell 
cyc le  proteins leading to speci fic chromatin acetylation and antiprol iferative effects . 
Thus, inhibition of  HDACs can be considered a new strategy for anticancer treatment. 
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Chapter II: 
Aims and objectives 
I I . Ai m a n d  obj ective 
1 .  The'i obj ect ive : 
The need for the development of  new anticancer drugs is evident and of great 
importance for the future. Today cancer chemotherapy depends on a rather smal l  
panel of  compounds. With the enormous body of  knowledge which has been 
accumulated in the last few years in chemistry, cel lular and molecular biology, it has 
become possible to develop novel molecules which, for example, exert their cytotoxic 
actions on cell membranes and on signal transduction pathways. Thus, synthetic 
nuc1eosides which possess ant i-twnor activity are gaining increased importance as 
potential therapeutic agents. 
The aim of the present study was to fInd compound(s) that can destroy 
cancerous cel l s  with minute or no effect on the normal cells ,  uti l izing natural 
mechanisms such as apoptosis .  Thus the effects of four di fferent synthetic 
nuc 1eosides (coded : NIA, NlIA , NlIA and NIB) and their nucleobases (N-base l ,  N­
base2 and N-base3 ) were evaluated. The structures of these new nucleosides were 
establ ished using the most ad anced spectroscopic techniques to insure that all 
nucleosides had the correct structure with high purity. 
To address their cytotoxic effects, we concentrated on studying the abi l i ty of 
these analogues to induce apoptosi s  i n  human acute promyelocytic leukemia cel l  l ine 
(HL-60). In addition, some blood samples (normal and leukemic) obtained from 
leukemia Tawam Hospital were analyzed to observe the effect of these nucleosides on 
them. Moreover, further investigation was carried out to determine the apoptotic 
pathway orchestrat ing this action. Another focus area was ce l l  cycle regulation, 
chromatin modi fIcation and structure activity relationship (SAR) for the b iological 
enhancement of these compounds. 
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1 . 1 .  tudy  mod el: 
The HL-60 cell l ine was established in 1 977 from a patient with acute myeloid 
leukemia ( - 1 ) .  The cells largely resemble prornyelocytes but can be induced to 
d i fferentiate ill vitro. orne reagents cause HL-60 cel ls  to d ifferentiate to granulocyte­
like cel ls  others to monocyte/macrophage-l ike cel ls  (5 t ) .  
Resistance of cancerOLlS cel ls  to cytotoxic agents IS  one of the major 
challenges in  the face of successful chemotherapy ( 52,53). M ultidrug Resistance (MDR) 
is a relevant mechanism of  primary or acquired resistance in human leukemias and 
solid tumors (52 .32) . Hence vve have chosen HL-60 because it is considered a good 
model to study anti-tumor agents (5'1) , and other HL-60 strains that have M ulti -Drug 
Resistance (MDR) characteristic are avai lable, which wi l l  open a door for further 
investigation about whether our novel nuc1eosides contain improved bioactivity to 
potentiate the action of antimetabol ites and circumvent MDR. Another reason for 
choosing HL-60 cel l  l ine is the annual increase of new cases of cancer, particularly 
leukemia and lymphoma, in the Gulf area (1) . 
1 .2 .  Expected impacts of the work:  
There i s  an annual increase of new cases of cancer in  the UAE varying from 
one region to another depending on the spec ific type of  the cancer. The total number 
of malignant cases reported to Gulf Center for Cancer Registration (GCCR) ( 1 )  from 
UAE in 1 998 was 2 2 5 .  Males accounted for 1 27 (49. 8%) of  the cases and females 
accounted for 1 28 (50 .2%). In 1 998 the crude inc idence rate (CIR) of all malignanc ies 
in the Emirates population was 3 8 . 81 1 00,000 for males and 3 9.81 1 00,000 for females 
( \ ), compared to other countries in the area cancer incidence in UAE was the lowest. 
For example, the total number of mal ignant cases reported to GCCR from Bahrain in  
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1 998 was 3 4 3  ( I). Males accounted for 1 8 1  ( 52 . 8%) of the cases and females 
accounkd for 1 62 (47 .2°'0) ( I ) .  In 1 998 the crude incidence rate (CIR) of al l  
mal ignancies in the Bahraini population was 9 1 .61 l  00,000 for males and 8 3 .911 00,000 
for females ( 1 ) .  It was also reported that in Bahrain and UAE in 1 998, 4 .7% and 8 .6% 
of al l mal ignancies occurred before the age of 1 5  respecti ely ( 1 ) . 'vVhi le the total 
number of cancer cases r ported to GCCR from Saudi Arabia in 1 998 was 6227 (I). 
Iales accounted for 3 2·+3 (52 . 1 %) of the cases and females accounted for 2984 
(47.9°'0) of  the cases (I) .  In 1 998 the crude i nc idence rate (C1R) of al l  cancers among 
the audi population was 42.51 1 00 000 for males and 3 9. 71 1 00.000 for females ( 1 ) .  It 
is estimated that the 1 in istry of Health spends more than 1 60 mil l ion Dhs. on 
chemotherapy for treati ng UAE patients (I). Moreo er, a study by the National Cancer 
I nstitute C1 )  expected that a total of 1 ,3 68,030 new cancer cases and 563 ,700 
deaths in  the United States in 2004 (56) . World Health organization declared that most 
commonly occurring cancers found in chi ldren (0  to 1 4  years) are leukemia 
(particularly acute l ymphocytic l eukemia) ( 57) .  The work described in  thi s  study aims 
to provide a potential cost effective chemotherapeutic agent to treat cancer patients. 
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Chapter I II: 
Materials and methods 
I I I . M a terial a n d  method : 
1 .  N u cleo ide' and N u cleo ba e : 
ynthetic analogues that have been used in this study were suppl ied from 
Chemistry department fac ulty of Sciences at the UAE University from Dr. 
Ibrahim Abdou s laboratory (organic chemistry division). They \ ere synthesized 
according to s imi lar procedure publ ished in Molecules 2004 by Dr. Abdou and 
his col leagues. The chemical structures code names and R-groups of the 
analogues synthesized for testing are shovvn in Fig.  I I I .  1 , I I I .2 .  and Table . ! .  




I IA N I I A  
i l IA I E  
Fig. I l l . 1 : Structure and code names o f  nucleosides analogues; N1A, N I IA, NIllA and. NIB 
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Fig. l l l . 2 :  General nucleoside structure 
Table. I : l ucleo ides R a n d  R l  g ro u ps 
Co m p o u n d  R R l  
N IA P-C F3 Ac 
N I IA m-F Ac 
N I I I A  p- F  Ac 
N I B  p-C F3 H 
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2. B i o l og i c a l  a c t i v i ty :  
2. 1 .  Reaoen t  : 
'ucleoside analogues were synthesized and puri fied and then dissolved in  di­
methyl sulfoxide (DYfSO; S igma Aldrich Chemie GmbH Steinheim Germany) to 
pr pare 0 . 1 � 1  solution and stored at <woe. Protease inhibitors (P f F, leupeptin 
aprotenin and pepstatin A) acetyl- L-cystesine AC) and 2' , 7 -
Dichlorofluorescein diacetate (DCFH-DA) were acquired from Sigma Chemical 
Company ( igrna Aldrich, Germany). zDEVD-fmk (Caspase-3 inhibitor), zIETD-fink 
(caspase-8 inhibitor), z-LEHD-fmk (caspase-9 inibitor), and zV AD-fink (a general 
inhibitor of caspases) were obtained from Alex is  Corporation (Switzerland). 
Polyclonal and monoclonal antibodies \ ere obtained from sources l isted as fol 1ows: 
anti-Cyt c ,  ant i -VDAC, anti-ANT, anti - Bax, anti -Bak, anti-Bad, anti -Bc l-2, anti-Bcl­
XL, anti-p53 and anti-P ARP antibodies from Santa Cruz B iotechnology (CA, USA), 
anti -caspase-3 , ant i-Bid antibodies from Cell S ignaling Technology (New England 
Biolabs USA), ant i  HDAC- l ,  -2,  -3 and anti -Brg- l from Upstate (Upstate, USA). All 
the antibodies are polyc lonal except Bax ,  which i s  monoclonal. 
2.2. Tissue culture:  
Human promyelocytic leukemia H L-60 cel l  l ine (A TCC, USA) was grown in 
DMEM medium (GIBCO-BRL) supplemented with 20% fetal calf serum (GIBCO­
BRL), 1 00 units/rnl penic i l l in-streptomycin (GIBCO-BRL).  The cells were 
maintained at 3 7°C in 5 %  C02 incubator. After reaching confluency, the cel ls  were 
subcultured i nto 6-, 1 2- 24- or 96-wel ls  culture p lates, al lowed to grow for 1 -3 days, 
and treated with various concentrations of nuc1eosides and nucleobases, and other 
reagents. Fol lowing treatment, cel ls were harvested by spinning at 1 000 rpm for 1 0  
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minutes, washed with phosphate buffer sal ine ( PBS) ,  and used for several assays and 
protocols. 
Leukoc)tes from peripheral b lood \ ere harvested from normal individuals and 
leukemia patients ' blood samples that have been prescreened for contagious 
pathologies, as fol low: to each vol ume of blood three volumes of  Histopaq ue reagent 
(S igma, Germany) were added , and the mixture was spunspinned for 30 minutes at 
:WOO rpm at r o c .  Then the leukocyte l ayer was separated from serum and red blood 
cel ls layers . The leukocyte fraction was washed hvice with RPMI- 1 940 media 
(GIBCO-B RL) supplemented with 1 0% Fetal Calf Serum (GIBCO-BRL) and 1 00 
units/ml penic i l l in-streptomycin (GIBCO-BRL) by spinn ing at 1 000 rpm at 4°C for 
1 0  minutes each, and the partial ly purified leukocytes were cultured for testing. Cells 
were treated with various concentrations of  nuc1eosides and nucleobases, as well as 
other reagents. 
2.3.  M T T  ce l l  prol iferat ion a say : 
Cel ls  were plated i n  96-well plates at a density 4 x l 03 cel Is/wel l l l OO flL of the 
appropriate cul ture medium and treated with the compounds at concentrations of 1 2 . 5  
t o  1 00 flM for different t ime i ntervals (2-48 hrs) t o  determine optimum time and 
concentration.  In paral le l ,  the cel l s  were treated with 0 . 1 % of DMSO as a control .  A 
MTT [3-(4,5-dimethylthiazol -2-yl)-2,5 -diphenyltetrazol ium bromide] assay (Alexis, 
USA) was performed later according to the manufacturer instructions to examine the 
cytotoxic  effect of  these nucleosides. After adding the MTT reagent the plate was 
further incubated for 1 -4 hrs. fol lowed by measuring the absorbance .  This assay is  
based on the ce l lu lar c leavage of the tetrazol ium salt, MTT, into formazan that is 
sol ub le  in ce l l  cu lture medium and is  measured at 450 run directly in  96-wel l  assay 
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plates. The amount o f  the forrnazan dye (absorbance) generated by the activi ty of  
dehydrogenases in ce l l s  by  the intact mitochondria i s  directly proportional to  the 
number of l i v ing cel ls in culture. All nuc leoside compounds tested were dissolved in 
OM 0 (0. 1 1 stock solution) and subsequently d i luted in the culture medium to 
obtain the final concentrat ions that are going to be tested 1 2 .5 to 1 00 �M) before 
treatment of the cultured cel ls .  After thi s assay we noticed that DMSO did not ha e 
any effect on the iab i l i ty of the control cel ls, so untreated cel ls  (without DMSO) 
were chosen as negat i e control (viab le). 
2A. Flo\\ cy tometry :  
The translocation of  the membrane phospholipid phosphatidyl serine from the 
inner part to the outer part of the plasma membrane (an early apoptotic marker), was 
detected wi th an Annexin V-FITC staining kit (BD B iosciences, USA) on H L-60 
cel ls  treated with various concentration of nucleosides. Propidiurn iodide (PI)  was 
used to d ifferentiate apoptotic cel ls  wi th preserved membrane integrity (Annex in +, 
P I- )  from necrotic cel ls  that had lost membrane integrity (Annexin (-), P I(-)) .  After 
staining, the percentage of apoptotic cel ls under various treatments was analyzed by 
flow cytometry (F ACSCall iber, B ectonDickinson, USA). 
2.5.  DNA fragmenta t io n :  
To detect formation of  i ntemucleosomal fragments, D A was extracted from 
HL-60 cel ls  exposed to nucleosides and nucleobases for 1 6  hrs .  After harvesting, 
washing with PBS,  and fixation in  70% cold ethanol, degraded o l igonucleosomal 
D A was i solated with 40 �l of 0.2 M phosphate-ci trate buffer, pH 7 . 8 .  This was 
fol lowed by treatment of the extracts with RNase ( l mg/ml) ,  nonidet NP-40 (0.025%), 
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and proteinase K ( 1  mg ml)  for 1 hr at 3 re. The D, A was purified with phenol­
chloroform ( I :  1 )  fol lowed by prec ipitation in 1 00% ethanol and resuspention in  IE 
buffer ( 1 0  ffi. L pH 7 . 5 ) .  D A samples were resol ed by electrophoresis at ..J.OY for ..j. 
hrs on 1 . 5°'0 agaro e. and the Jaddering pattern was v isual ized by ethidium bromide 
staining with a transi l iminutesator (B iodoc analyzer B iometra Germany) , 
2.6.  Detect ion  of  DNA c leavage by fo rm a m id e :  
Chromatin  condensation was detected by use  of  formamide with an 
APOSTA E LISA kit (Alexis USA) according to the manufacturer's instructions. 
Cel ls  were cultured in  96-wel l  plates at a density 4x 1 03 ce l ls/wel l  i n l 00 iJ-L of the 
appropriate culture med ium and treated with the compounds at various concentrations 
( 1 2 . 5 ,  2 5 ,  50 and 1 00 iJ-M) for 1 6  hrs. DNA was denatured by heat ing in the presence 
of formamide and the denatured D A was stained with monoclonal antibody (MAb) 
F7-26 that is  spec ific  to s ingle stranded DNA (ssD A) in  the E LISA format. 
2 .7. ,"Vestern b lot  an alysis : 
Cells treated with nucleosides were harvested, washed once with PBS,  and 
resuspended in a lysis buffer containing 1 00 roM Hepes, pH 7 . 5 , 1 0% sucrose, 1 0  mM 
DTT, 0 . 1 % C HAPS, 1 50 roM aCl ,  and protease inh ibitors ( 1  roM P M  SF and l iJ-g/ml 
each leupeptin, aprotini n, and pepstatin A). For the experi ment with caspase 
inhibitors, the cel ls  were pre-incubated 1 0-30 iJ-M of zIETD-fmk (caspase-8 inhibitor) ,  
zLEHD-fmk (caspase-9 inhibitor), or  zDEVD-fmk (caspase-3 inhibitor) or  with 50 
iJ-M of zV ADfmk (the general caspases inhibitor) for 4 hrs . Next, the cel ls  were 
exposed to nucleosides and their  nucleobases for 8 1 6, or 24 hrs, except for the 
control cel ls,  which were untreated (without DMSO).  The harvested cel ls  then were 
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lys d by 5 -6  cons cuti " e cycles of  freeze and thaw, and spun at 1 .. +000 rpm for 30 
minutes at 4°C. The supernatant was separated [rom the pel let  and used immediately 
or stored at -80°C. Protein in the cel lu lar extracts was quanti fied with an assay kit  
based on the Bradford colorimetric reaction (BioRad, SA). Cel l protein  (40 Ilg per 
lane) was analyzed on 8%, 1 0% or 1 2% SD -polyacrylamide gels and electroblotted 
onto PVDF membranes ( l i l l ipore, USA). After the transfer, the membranes were 
blocked \\ i th 5°10 nonfat dry mi lk and 0 . 1 % Tween-20 for 1 hOUT. The membranes 
were then incubated at -+ °C overnight with the ant ibodies, d i luted as folows: 
• 0 . 1 �0 Tween-20 and PB for :  anti-PARP ( 1 : 1 000 d i lution), anti­
V DAC ( 1 : 1 000), anti-A T ( 1 : 1 000), ant i-Bc 1-2 ( 1 : 700), anti-Be t-xl 
( 1 :  1 000), anti-Ba.x ( 1  : 500),  ant i-Bad ( 1 :  1 000), ant i-Bak ( 1 :  1 000),anti­
HDAC I ( 1 : 1 000), anti -HDAC2 ( 1 : 1 000), ant i -HDAC3 ( 1 : 1 000), anti­
Brg 1 ( 1 : 1 000), 
• � %  nonfat dry mi lk  in  TBS and 0 .05% Tween-20 for anti-caspase-3 
( 1 : 1 000 di lution), 
• In 0 . 1 %  Tween-20 and 5% bovine serum albumin for anti-Bid 
( 1 :  1 000), 
• 2% nonfat dry mi lk in  0 . 1 %  Tween-20 and PBS for both anti­
cytochrome c ( 1  : 2000 d i lution) and anti-p53 ( 1  : 5 00) .  
The b lots then were incubated with the appropriate horseradish peroxidase­
conj ucated secondary antibodies ( 1  : 2000 d i lution). The antigen-antibody interaction 
on the b lots was detected by a S uperS ignal chemiluminescence kit  (Pierce, 
Biotechnology Rockford, IL ,  USA) and visual ized by autoradiography. To confirm 
equal loading of  proteins, the b lots were immunoprobed with a rabbit polyc lonal 
antibody against the c ytoskeletal protein /3-tubul in ( 1  : 25 00 di lution in 0 . 1 % Tween-
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20 and PB ) .  \Vestem blots v"ere scanned and analyzed quantitively by measuring 
band intensities with Biodoc analyzer, Biometra, Germany. 
2.8 .  Relea e of cytoc h ro m e  c: 
To assess the effect of nucleosides on mitochondria, freshly isolated 
mitochondria extracted from the cel ls  treated with 50/lM of nuc leosides for 4 and 1 6  
hrs by di fferential centri fugation and resuspended i n  H-medium (70 mM sucrose, 220 
nllv1 manito ! ,  25  m 1 Hepes pH 7.4 2 mM E DTA pH 8 ,  1 mM DTT and 0 . 1 mM 
P I F) were incubated at 30°C for 30 minutes in  1 0  mM Tris-HCI pH 7.4 containing 
0 . 1 5  f KC! and 5 mM succinate. The incubated samples were centrifuged at 8000 g 
for 1 0  minutes at 4 DC. Then the supernatant was separated from the pellet 
(mitochondria) and both mitochondrial (20 /lg) and cytosolic ( 5 0  /lg) fractions were 
analyzed by Western b lot with an anti-cytochrome c antibody. 
2.9 . . Meas u re m e n t  o f  m i tocho n d ria l  m e m b ra n e  p o te n t i a l :  
The decrease in  mitochondrial transmembrane potential in ce l l s  treated with 
nucleosides was measured by a MitoCapture™ apoptosis detection kit (Alex is 
B iochemicals, USA) according to the manufacturer's i nstructions. After the treatment 
vvith different concentrations of nuc leoside analogues for 1 6  hrs, cel ls  were harvested 
and incubated in 1 ml of i ncubation buffer containing Mitocapture™ dye ( 1  /lglml )  
for 20 m inutes a t  3 7DC in  5% C02 incubator. After that the ce l l s  were col lected by 
spinning, and the percentage of the green fluorescence was determined by flow 
cytometry. 
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2 . 1 0 . Dete r m i n at ion  of  i n t racel l u l a r  react ive oxygen pecie ( ROS)  fo rmat ion : 
\ l ea urement 0 f RO or intracel l  ular peroxides was performed by using 2 ' ,  T ­
dichlorofluorescin diacetate (DCFH-D ) ,  "" hich is  de-esteri fied b y  endogenous 
est rases within cel ls  to ionized free acid (2 ' . 1 '  -dichlorofuorescine; which in turn is 
oxidized by hydropero. ides to the fl uorescent form 2 '  , 1 ' -dichrolofluoresc in (DCF) 
1 0  rru\1 DCFH-DA was prepared in D 1S0 (dimethylsulfoxide) as a stock solution. 
H L-60 cel ls  ( 1  x l  06) were cultured overnight in 6-well culture plates. After treatment 
\-\ ith nucleo ides for di fferent time intervals (4, 8, 1 6, 24 hrs), cel ls  were further 
incubated for 1 5  minutes with 1 0  mM DCFH-DA at 3 7°C . They were then washed 
\. ith pre-warmed medium fol lowed by ice-cold PBS, harvested by spinning at 1 000 
rpm for 5 minutes and resuspended in PBS containing 1 0  mM E DT A. The formation 
of ROS was measured with F ACSCal l ibre flow cytometer. To study whether the 
inhibit ion of ROS could prevent apoptosis induced by nucleosides, cel ls were 
pretreated with 2 . 5 ,  1 0  mM N-acetyl-L- cysteine (NAC). 
2 . 1 1 .  Ce l l  cyc le  a n a lysis : 
The proportion o f  cel ls  m Go-G I , S ,  and G2-M was determined by flow 
cytometric analysis o f  DNA content. Cel l  cyc le distribution m H L-60 cel ls was 
measured after 1 6  hrs o f  treatment with nucleosides. Briefly, 1 x 1 0
6 cel ls were 
harvested, washed twice with cold PBS, then they were fixed overnight in 1 0  ml of  
70% (-20°C) ethanol a t  4°C.  Subsequently, ce l l s  were washed twice with co ld PBS 
incubated with RNase (0 .25  mg/ml) at 3 7°C for 1 hr, and stained with PI ( 50  llg/m1 in  
PBS)  for 30  minutes at  4°C in  the dark fol lowed by flow cytometry. 
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2. 1 2 . t a t i  t i cal a n al) i 
All  experiments were repeated at least three times. Data were general ly 
expres ed as mean ::t: tandard deviation ( D) from three independent experiments . .  
tat i t ics were calculated and plotted b y  Excel soft\-vare. For the (TT assay each 
oncentration \\ as tested in tripl icate and the whole experiment was repeated thrice. 
To measure the percentage of  viabil ity the value of the negative control (cel ls treated 
with 0 . 1 0 0 DM 0 or untreated cel ls ) was subtracted from the posit ive control ( cel ls  
treated with 0. 1 % D ) after dividing both numbers over 1 00 (volume used), then the 
ab orpt ion of each trial was multipl ied with this value, then the data were blotted by 
Excel after measuring the standard deviation. The F ACS experiments were repeated 
also three times. The mean and the standard deviation values were calculated. For the 
Westem blot analysis,  a representative gel wi l l  be shown and the mean band intensity 
yalue of target proteins wi l l  measured and blotted by Excel after calculating the 
standard deviation. Below is a time scale of the experiments that have been conducted 
i n  this study (Fig .  III.3). 
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Fig. 1 1 1 .3 :  time-scale representation of the experiments that were conducted in this study. MTT assay 
was the flfst to used to determi ne the optimum time and concentration, fol lowed by Annexinl PI for 
further confirmation. To determine the events in the process of cel l  death induced by these nucleosides 
further assay such as ROS, measurements of m itochondrial membrane potential , Western blots and 
cel l  cycle analysis were performed. 
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Chapter V I: 
Results and discussion 
I V. Re u l t a n d  d i  c u  ion : 
1 .  Res u l t : 
1 . 1 .  Red u c t i o n  i n  H L-60 p ro l i ferat ion a n d  i n tegrity by l A, I I A a n d  N I I IA :  
The HT cel l  pro l iferat ion assay showed that there was a decrease in the 
absorbance and therefore the viabi l i ty of the cel ls with increased concentrat ions 
of the nucleosides. \Ve found that NIA and NIIA are the most effective 
compounds ev n when 1 2 . 5  �M was administered, which is below the inhibitory 
concentration 50 (lC50). r quired to inhibit the grovy-th of 50 % of any system, 
and in this case it was 50 �M (see F ig. IV. l a  and b) .  On the other hand, NIB 
which has the same structure as NIA except that i ts  sugar is  non-acetylated, 
showed no anti-twnor activity. This result indicated that this analogue either 
protects against apoptosis or has no effect at al l .  This finding also suggested that 
acetylated sugar increases the b ioavailabi l i ty (their delivery i nto the cel l )  of the 
nucleoside and therefore its effect iveness . To test i f  the chemical structure of the 
base alone has any role in the cytotoxicity, we exposed cel ls  to NIA with sugar 
presented or removed and tested them using flow Cytometry by Annexinl P I  (see 
section N. l .2) .  Test of  NllIA revealed that i t  has reduced b ioactivi ty compared 
to the other nucleoside analogues. Interestingly, NllIA shares the same chemical 
composition with NIIA, except the position of  the fl uorine in  NITA i s  para, while 
in  NllIA i t  i s  meta, which indicates that there was a structure-activity 
relat ionship (SAR)  determining the cytotoxic effect of these analogues. The 
init ial observat ions about the apoptotic potential of these drugs in  the HL-60 cel l  
l ine prompted us to further i nvestigate the mechanism of  their apoptoti c  
induction. The controls  that were used in these experiments i f  not spec ified were 
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untreated cel ls  as negative control and Etoposide (a known anti-cancer agent that 
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Fig. I V. 1 :  Viab i l ity and l Cso determi nation from MTT cel l  pro l iferation assay. H L-60 cells were treated 
w ith the various compounds l isted at concentrations ranging from 1 2 .5 to 1 00 /lM for d ifferent time 
intervals (2-48 hrs) to determine optimum time and concentration. I n  paral lel ,  control cells were treated 
with 0. 1 ero DMSO: a) Decrease in the viabi l i ty of the ce l ls w ith increased concentrations of the 
nuc leosides, b) I Cso value of the nuc leoside (NIA). L ine p lot represents % of viabil ity of different 
concentration ± SD, n= 3 .  
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1 .1 .  po ptot ic  effect  o f  the novel n u cleos i d e  o n  H L-60 cell viabil ity: 
To confilm the data obtained \I/ ith MTT, HL-60 cel ls  were treated with 
various concentrations of  the nuc leosides for 2 4 8 1 6, and 24 hrs. The cel l  
death \\ as measured by Annexin staining technique. In this assay the loss of 
plasma membrane asymmetry, which is  one of the earliest features of  apoptosis, 
was targeted b the binding of Annex in V to the membrane phosphol ipids 
phosphotidylserine (PS) that is translocated from the i nner to the outer leaflet of 
the plasma membrane of  apoptotic cel ls .  Because PS translocation also occurs 
during necrosis ,  Propidium iodide (P I) is used in conj ugation with Ann ex in V .  P I  
can only penetrate the plasma membrane when membrane i ntegrity is  breached, 
as occurs in the later stages of apoptosis or in necrosis .  Cel ls that are negative for 
both Annexin V and P I  (Annex in  ( -) P I  (-)) are considered viable  cel ls (not 
apoptotic) while the cel ls that are stained Annexin V positive and are P I  
negative ( Annex in  (+) P I  (-)) are considered to  be early apoptotic cel ls .  On the 
other hand, the cel ls  that are positive for both Annexin V and P I  (Annexin (+), P I  
(+)) are late apoptotic cel ls,  and those that are Annexin V negative, P I  positive 
(Annexin ( -) ,  PI (-))  are recognized as necrotic cel ls .  The results obtained from 
this assay (see Fig. IV.2)  supported those from MTT cel l  pro l iferation assay (see 
Fig. IV. I ), in which that IA was the most potent analogue as i t  resulted in more 
that 5 0% apoptosis compared to the positive control (Etoposide) fol lowed by 
NITA then NIIIA. This assay also indicated that the nucleobases are the cytotoxic 














• 25uM ( 1 :-1000) 
o 50uM (I :2000) 
control Etoposide NlA NUA NillA -base3 -base 2 -base I o 100uM ( I :  1 000) 
Fig. I V . 2 :  ummary of flow cytometric analysis of HL-60 cells treated with different 
concentrations of the nucleosides for 1 6  hrs b, Annexin V, PI . mean values of apoptosis % were 
calculated I SD, n= 3 .  
�v loreo\'er a time- and concentration-dependent i nduction of apoptosis 
was observed in  the cel l s  treated with lA, I lA and IlIA. The concentration-
dependent data represent NIA (the most effective analogue), while the time point 
study was carried with 50 �M s ince it was the concentration required to induce 
50% of the cell death (see Fig(s). IV .3  and IVA) .  A gradual increase in  the 
percentage of apoptotic cells was observed at 1 6  hrs compared with the control 
cel ls (untreated cel l s) (see Fig. IVA).  Increasing the incubation time up to 24 hrs 
resulted in significantly higher apoptotic rates, reaching 7 5 A5% at 1 00 �M for 
NIA (Fig.  Iy'3) .  As for NIB,  it did not differ form the control , and even at 50 
11M the n umber o f  viable cel l s  was higher than that of  the control (9 1 . 1 4% while 
control was 89. l 6%) (data not shown, but not statistically significant, p>0.05) .  
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Fig. lV.3: Representative flo\ cytometric analysis of the time - and - concentration-dependent 
induction of apoptos is in the HL-60 cells treated with N lA, by use of Annexin-V / P I :  a) control 
(untreated cells), b) 50 !lM IA for 4 hrs, c) 50 !lM N I A  for 8hrs, d) 50 !lM NLA for 1 6  hrs e) 50 !lM 
IA for 24hrs f) l OO !lM l A  for 24 hrs. The arrows point to the % of cel ls in each quadrant: viable 
cells ( lower left), early apoptotic cells (lower right), late apoptotic cells (upper right) and necrotic cells 
(upper left), n=3 . 
Surprisingly, it seems that these nucleoside analogues have a low necrotic 
i ndex ( 1 .7 in  NIA) compared to the Etoposide (4 .5%) (Fig.  IV.4) .  Also i t  seems 
that the acetylated ribose found in N IA, IIA I l IA did not play a role in the 





apoptolic e ffect of 1 I I I  is  not due to the sugar differences, but is rather a r suit 
of the structure d ifference and the chemical composition of the analogues. 
Furth rmore, thi s  confirmed that the importance of the sugar l ies in increasing 
nuc leoside avai labi l ity within the cel ls ,  thus indirectly enhancing their 
c)1otox i  i t) . 
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Fig. I V A :  Representative flow cytometric analysis of the concentration-dependent induction of 
apoptosis in the cel ls  treated with NIA, NlIA and N I l IA for 16 hrs by use of ArU1exin-V/PI :  a) control ,  
b) 1 2 .5 IlM lA, c) 25 IlM NIA,  d) 50 IlM N IA, e) 1 2 .5  IlM Nl IA, f) 25 IlM Nl IA, g) 50 IlM N l IA, h) 
1 2.5 11M I I IA, I )  25 11M I l IA, j )  50 11M N I I IA, k) 25 11M Etoposide, I) 1 00 11M acetylated ribose, m) 
50 11M N-base I ,  n=3 . 
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1 .3 .  E ffect o f  � I  , 1  I I A a n d  N I I I A on normal  a n d  l e u kemia  b lood a m p le : 
ext, \\ e analyzed the effect of  these nucleosides on peripheral blood 
cel ls  of leukemia  patients in the area as ,,\'el l  as normal individuals (this 
experiment was repeated three t imes and the blood was obtained from four 
patients repre enti ng each case. and from three normal individuals) , Leukocytes 
were iso lated from nom1al and leukemic blood samples obtained from Tawam 
ho pital and treated with different concentrations o f  nucleosides for 1 6  hrs 
(optimum time). Flow c)10metric analysis of leukocytes from normal i ndividuals 
sho\\ ed that these analogues had only a minute cytotoxic e ffect even at high 
concentrations c:�00 �M) (see Fig. IV.5) .  
Control 
= 1 
3 23% ; 
50 11M NL-\ J 00 11;\[ N IA 
. ...-- --,-- --1 2 . 880/:" . 
� � I " }----.-,.I""c-''-:--- 2 . 97%::! �;- -'.::::-'4"-----1 
200 11M 1\'1",\ 
F ig. I .5:  Representative flow cytometric analys is of four normal blood samples by Annexin 
V PI ,  shov. ing the effect of these analogues on normal leukocytes; a) contro l, b) 50 ).lM N IA, c) 
1 00 ).lM NlA, d) 200 ).lM lA, n=3 . 
On the other hand 50 �M of the nucleosides significantly affected the 
white blood cel ls  i solated from the four leukemia patients treated for 1 6  hrs (Fig. 
IV.6-8) .  lA, lIA and Il IA were tested on three d ifferent types of  leukemia: pre-
B-cel l  acute lymphoblastic leukemia, acute T - lymphoblastic leukemia and acute 
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5. 30% 
3 . 38% 
myelogenic leukemia. These nucleosides \-vere effective against lymphoblastic 
leukemia espec iaU) pre-B-cel ls, reaching 78 . 34% of apoptosis when 50 ).ltv! of 
i IA \vas admini tered for 1 6  hrs, whi le  in  the case of  acute T lymphoblastic 
leukemia it was 1'2 . 1 80 0 with 50 ).l 1 I . Treatment of  myelogenic leukemia 
was not effective as indicated with negligible apoptosis percentages ( 1 .26% 
compared to the control ) .  Interestingly, the necrotic index of these analogues 
( 1 . 7�0) was lower than that of Etoposide (4 .5%) (Fig. IVA).  Together. these data 
indicate that IA. I lA and ILIA have minimal effect on normal leukocytes as 
well as myelogenic leukemia with low necrotic rate and sign ificant cytotoxic 
effect on acute lymphoblastic leukemia. 
Co n t rol 50 /1 M  NL\ 50 /1,\ [ N I  L \  5 0  /11\ ) , l i lA 
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Fig. [ V.6:  Representative flow cytometric analysis of four pre-B-ceL l  acute lymphoblastic leukemia 
sample by use of  Annexin  VIP! , a) control, b) 50 11M N lA, c) 50 11M N l lA, d) 50 11M Nl I lA,  n=3 . 
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Fig. 1 .7 : Represenlati e flow cytometric anal) sis of four acute T- lymphoblastic Leukemia sample 
using Annexin 'P I . a) control ,  b) 50 � I NLA, c) 50 �M N I fA, d) 50 �M N l l IA, n=3 . 
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Fig. I V.8:  Representative flow cytometric analysis of four acute myelogenic leukem ia sample using 
A nnexi n  V 'P ! ,  a) control, b) 50 �M N lA,  c) 50 �M l l lA d) 50 � M  N I I I A  n=3 . 
1 .4. I nd uction o f  DNA frag m e n tat ion a n d  c h a n ges III c h r o m a t i n  condensation 
pattern by N IA, N I I A  and N I I IA :  
D A fragmentation and chromatin condensation are hal lmarks o f  
apoptosis .  Therefore, the abi l i ty of  nucleoside analogues and their corresponding 
bases to i nduce i nternucleosomal DNA degradation and chromatin condensation 
within 1 6  hrs were tested on HL-60 cel ls (see Fig. IV.9) .  The nucleosides and 
their corresponding bases were tested at two different concentrat ions (25 and 50 
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Fig. IV.9:  D A fragmentation assay i n  HL-60 cells treated with nuc leos ides and nucleobases for 1 6  
hrs. The laddering was detected on 1 %  agarose gel, and an increase i n  the intens ity o f  the ladder was 
observed with increased concentrations. A). Representati ve agarose gel of DNA fragmentation (n=3) 
; I ). I Kb ladder, 2) Control (untreated cells without DMSO), 3)  25 JlM N IA, 4) 50 !-1M NIA 5) 25 JlM 
-base 1 , 6) 50 JlM -base I ,  7) 25 !-1M HA, 8) 50 !-1M Nl lA,  9) 25 JlM N-base 2, 1 0) 50 JlM N-base 
2, I I ) 25 JlM N l I lA, 1 2) 50 JlM N l I lA, \ 3 ) 25 Jl M  N-base 3, 14)  50 JlM N-base 3 .  B). Quantitative 
normalized measurements of fragmented band intensity (means ± SD). 
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The intemuc leosomal fragments of  D A were isual ized as a ladder on 
1 %  agarose gel . n increase in the intensity of  the ladder was observed with 
increasing concentrations of each agent ( lanes 3 -6) .  D A c leavage products 
representing internuc leosomal fragment were vis ible in response to 50 �M and 
even in 25 �l 1 cone ntrations of the nuc leosides °IA nad NIlA compared to 
their bases, and this supports the finding that the base is the toxic part of the 
nu leoside not the sugar (see Fig. IV.9) .  
1 ucleoside analogues and their bases also induced DNA denaturation in  
the pre ence o f  formamide in a concentration dependent manner (F ig. IV . l 2) .  
IA gave the maximum percentage of  chromatin condensation fol lowed by 
N ITA. NIIIA and its base were similar in this i nduction. These results were 
consistent v ith the data obtained previously from FACS and MTT assays (see 
F ig. IV. 3 - 1 0) .  Whereas histones are responsible for stabi l izing DNA structure 
against thern1al denaturation (55),  these results suggest that histone digestion may 
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Fig. I . l O : Detection of chromatin condensation in a concentration-dependent manner by fonnamide. 
D A denaturing was examined with an APOSTAIN ELISA kit according to the manufactllJer's 
instructions. Briefly, DNA was ftrst denatUJed by heating in the presence of  fonnam ide. I n  the second 
step the denatured D A was stained with monoclonal antibody (MAb) F7-26 spec ific to single 
stranded D A (ssD A) in ELISA format. The negative control was untreated cel ls ,  while the positive 
control was single stranded DNA supplied by the manufacturer. Line p lot represents % of chromatin 
condensation ::: SD, n= 3 .  
1 .5. E ffect o f  n ucleosides o n  the exp ression o f  key a popto tic p rotei n s :  
During apoptosis a group of proteolytic enzymes cal led caspases are 
activated in a cascade-fashion, leading to the activation of  the "executioner 
caspases", such as caspase-3 .  These executioner caspases are responsible for the 
destruction of the key ce l lular proteins such as DNA repair enzymes that leads to 
the typical morphological changes observed apoptosis (33, 34). Therefore the effect 
49 
o f  nuc leosides on the expression o f  c leaved caspase-3 was analyzed by \Vestem 
b lotting (Fig .  IV. l l ) . 
The induction of  the c leaved fonn was detected at 2 5  50,  1 00 � . This 
acti vation of  the effector (executioner) caspase was assessed at 1 6  hrs and 24 hrs 
as \\- e l l .  This concentration-dependent induction resembles the reduction in 
viab i l i ty and D A fragmentation observed previously, in that NIA i s  the most 
effective one fo llowed by NITA (although there was no change in the expression, 
but the intensity was prominent), then NI I IA .  
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Fig.  N. l l :  Expression o f  c leaved caspase-3 (p 1 9) and the full length (upper band) in HL-60 cel ls 
treated with various concentrations of  nucleosides and nucleobases for 16 hrs.  40 Ilg of Whole cel l  
extract were loaded on 1 2% SDS-PAGE and probed with anti-caspase-3 . A). Representative Western 
of three independent experiments. B). Quantification of p ]  9 band intensity of the nuc leosides N TA, 
I lA and N I I IA .  C). Quantification of p 19 band intensity of  the nuc leobases, (means ± SD, n=3) .  
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One of  the essential target proteins required for cel l  viab i l ity is the DNA 
repair enzyme PARP poly (ADP-ribose) polymerase) ( 59-6 1 ) .  Cleavage of PARP 
by caspase-3 1 ads to D A fragmentation (62-67) . To invest igate the activation of 
P ARP nucleosides treated cel ls  were b lotted with P ARP polyc lonal antibody. 
The 1 1 6 KDa PARP was c leaved into a 89 KDa fragment at 25 ,  50 l OO !lM 
concentrations of the nuc leosides and nucleobases (Fig .  IV. 1 2) ,  and this result 
was consistent with the increased caspase-3 acti ity observed, in which 50 !lM of 
lA and NIlA was enough to cause complete loss of the 1 1 6  KDa fragment. 
foreover, these observations support the finding that NIA is the most effective 
tested compound, and this is  based on comparing the intensity of the 85 KDa 
band and the disappearance of the 1 1 6 KDa fragments. 
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B. Concentrations c. Concentrations 
F ig. I V. l 2 : PARP cleavage in H L-60 cells in the presence of different concentrations of nucleosides 
and nucleobases admin istered for 1 6  hrs. 40 �g of cel l  extract was loaded on 8% SDS-PAGE, and 
b lotted with ant-P ARP. A). Representative Western of three independent experiments. 8).  
Quantification of  cleaved PARP band intensity of the nucleosides. C). Quantification of c leaved PARP 
band intensity of the nuclebases (means ± SD, n=3). 
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'ext, we examined the expression of  the BcI-2 family proteins. The Bcl-
2 proteins are a group of proteins involved in the resistance against or 
enhancement of apoptosis .  Some of these proteins (such as Bcl-2 and Bc I-xl) are 
anti-apoptotic, whi le others (such as Bad, Bak, B id or B ax)  are pro-apoptotic .  A 
concentration-dependent decrease in the expression of  Bc 1-2 and BcI-xl was 
detected in H L-60 pretreated with nuc leoside analogues, especial ly with the 
treatment at 5 0  11M and 1 00 11 f of IA and IrA (Fig. IV . 1 3) ,  whi le a consistent 
increase in Bax, Bad, Bak and induction of truncated Bid was observed (Fig. 
IV. 1 3 ) .These results indicate that these nucleosides might induce apoptosis 
through the mitochondrial pathway, beacuse Bc l-2 family members have been 
shown to control Cyt c release from the mitochondria (58) .  The abi l i ty of Bax to 
induce the efflux of Cyt c within minutes after its translocat ion from the 
mitochondria have been reported (58) A concentration dependent increase in the 
expression of the tumor suppressor protein p53 was observed; again this was 
m uch c learer in the case of NIA and N1IA ( 5 0  11M and 1 00 11M) .  
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F ig. IV. 1 3 :  Effects of various concentrations of nucleosides and nucleobases appl ied for 1 6  hrs on the 
expression of the anti-apoptotic proteins, Bel-2 and Bel-xL. and pro-apoptotic protei.ns Bax, Bad, Bak, 
B id, and on p53 . 40 �g of H I-60 cells extract was loaded on 1 2% and 8% SDS-PAGE. and probed 
with the coressponding antibodies. Representative Western of three independent experiments. 
1 .6. E ffect of casp ases i n h i bitors on N IA, N I I A  a n d  Nl I IA- st imulated 
activation of cas pase-3 : 
To understand the events proceeding caspase-3 activation and apoptosi s  
i nduced by  nucleoside analogues, we  examined the effect of  various caspase 
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Fig. rv. l .t :  Determination of apoptotic pathways with different concentrations ( I  0-30 �M) of caspases 
inhibitors; i nc luding z-V AD (general inhibitor), z-IETD (caspase-8 inhibitor), z-LEHD (caspase-9 
inh ibitor), z-DEVD (caspase-3 inhib itor). These inhib itors were added 4 hrs before adding the 
nucleosides (50 �M) for a6 hrs, then a Western blot analysis was carried on w ith anti-caspase3 .  A). 
Representative Western blot with anti-caspase3 of three independent experiments. B). Quantification of 
p 1 9  c leaved caspase3 band on post treatment with NlA , C). Quantification of p 1 9  cleaved caspase3 
band on post treatment with N l lA, D). Quantification of p 1 9  c leaved caspase3 band on post treatment 
with N I I lA,  (means ± SD, n=3). 
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B fore incubation of cel ls with nudeosides (50  III 1) ,  they were treated 
for 4 hrs in the absen e and presence of ( 1 0-30 11M) of zIETD-fmk (caspase-8 
inl1 ibitor), zLEHD-fmk (caspase-9 inhibitor), zDEVD-fmk (caspase-3 inhibitor), 
or \\ith 50 11M of zV ADfmk- the general inhibitor of caspases. The result of 
c leaved caspase-3 immunoblotting sho\',:ed that the increased concentrations of 
caspase-8 inhibitor did not sign ificantly change the nucleoside-induced 
apoptosis, whi le there was a nearly total inhibition observed at preincubation 
with increased concentrations ( 1 0-30 11M)  of caspase-3 ,  -9 and z-V AD. These 
resul ts demonstrate the critical role of caspase-9 activation in NIA, NIIA and 
NIIIA-induced apoptosis .  
1 . 7. E ffect o f N IA, N I IA a n d  N I IA o n  t h e  release o f  C y t  c fro m 
mitoc h o n d ria:  
According to the above resul ts, induction of  the apoptotic machinery by 
the nuc leoside analogues was caspase-9 dependent. This caspase is  part of the 
apoptosome (caspase-9 and Apaf- l )  that triggers the release of Cyt c from the 
m itochondria into the cytoplasm (58-60,65,66) . Therefore, the cytosol ic and 
mitochondrial fractions were prepared from cel ls  treated with 50 11M of 
nucleosides and their  bases and Cyt c expression was detected by Western b lot. 
Release of  Cyt c in the cytosol ic fraction was detected after 8 hrs inc ubation with 
nucleosides (Fig. IV . I S) with a disappearance in the mi tochondrial fraction for 
all the nudeosides with the exception of  bases, in which some of  Cyt c was 
detected in the mi tochondrial fraction. To study the relation between NIA, ITA, 
IIIA- induced apoptosis and Bax, we examined the kinetics of Cyt c release and 
expression! upregulation of Bax .  Cyt c release from the mi tochondria was 
5 7  
detected a early as 8 hrs after incubation with nuc leosides and nucleobases, but 
i t  was c learer after 1 6  hrs of incubation (v,:ruch is the optimum time of incubation 
with these nucleosides) (Fig. IV. 1 5),  while increase in Bax expression was 
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Fig. I V. I S :  Release of cytochrome c after nucleos ide adminstration for 1 6  hrs and involvement of Bax 
in the ampl ification of Cyt c release. The cytosolic and mitochondrial fractions were prepared from 
cells treated with 50 ).lM of nucleosides and the ir bases. Then 20 ).lg of mitochondrial and 50 ).lg of 
cytosolic fractions were analyzed by Western blot. A). Representative Western of three independent 
experiments. B). Quantification of Cyt c level in the cytosol after nucleosides treatment, 
C).Quantification of translocated Bax level into the mitochondria after nucleosides treatment, (means ± 
SD, 0=3 ). 
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Interestingly, there was a Bax translocation to the mitochondria at 1 6  hrs 
after nuc leosides treatement (see Fig.  ry . 1 5), \vhich suggests that, i) NIA. IIA 
and I l IA, and their bases initiated apoptosis through a direct effect on the 
mitochondria, which resulted in Cyt c. release, and i i )  the apoptotic signal was 
further ampl i fied by the translocation of Bax . Up- regulation of Bax is control led 
by p':-3 (Fig. I . 1 3 ). v. hich is  a tumor suppressor protein induced in response to 
Dl A damage (351. We showed that D A fragmentat ion by nucleoside analogues 
is dependent on caspase-3 activation; thus induction of p53 fol lows caspase-3 
activation. Furthennore, NlA, I IA and IlIA triggered a caspase-dependent 
truncation of Bid (see Fig. IV. 1 -'+) ,  which in addition to p53 ,  promotes 
translocation of Bax that subsequently enhance the release of Cyt c. The 
expression levels of VDAC which serves in combination with the proapoptotic 
members of Bcl-2 fami ly to fonn a pathway for Cyt c release from the 
mitochondria (34.:5), and its regulatory protein ANT were examined. There no 
change in their expression was detected (Fig. IV. 1 6) .  These observed changes in 
the expression o f  the Bcl -2 fami ly member might indicate that the release of Cyt 
c may take place also through different channels and mechanisms. 
5 9  
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B. Concentrations c. ConceFltrations 
F ig. I V . 1 6 : E ffect of dlfferent concentratIOns of nucleosldes administered for 1 6  hrs on cytochrome c 
releasing gates (VDAC and A T). 40 flg of H I-60 cells extract was loaded on 1 2% SDS-PAGE, and 
probed with the appropriate antibodies. A). Representative Western of three independent experiments. 
B).Quantification of A T band intensity after nuc leosides treatment, C).Quantification of VDAC 
Ie el after nucleosides treatment (means :t: SD, n=3) .  
1 .8. Alterations o f  m itoch o n d rial  m e m b rane p o t e n t i a l  o f  H L-60 cells :  
Changing the mitochondria membrane potential i s  bel ieved to be one of 
the mechanisms of Cyt c release (58-6 1 ) . Therefore the mitochondria membrane 
potential was measured with the MitoCapture™ cationic dye as per 
manufacturer' s  protocol .  In healthy cel ls ,  MitoCapture™ accumulates lTI the 
mitochondria and gives off green fluorescence, while in apoptotic cel ls ,  due to 
the altered mitochondrial membrane potential, the green fl uorescence remains in  
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the cytosol .  The nuc leoside-induced membrane depolarization could be observed 
either by the concentration-dependent decrease in the red fluorescence given by 
intact mitochondria or by the increase in the intensi ty of the green fluorescence 
in the cytosol of the treated cel ls .  In this assay, we examined the alteration in 
mitochondrial membrane potential by the decrease in the intensity of the red 
fluorescence (decrease in the number of healthy mitochondria) .  For example, in 
the control  (untreated cel ls), one peak with maximum red fluorescence intensity 
should be detected, and a decrease of the fluorescence and formation of another 
peak (corresponding to damaged mitochondria) should be detected as result of 
the administration o f  the nuc1eosides. 
Test of the nucleosides revealed that they induced mitochondrial 
membrane depolarization in a concentration-dependent manner (see Table2 and 
Fig .  IV .  1 7) .  25 )lM of IA altered the potential of 62 . 1 2% of the mitochondria, 
while 5 0 )l f disrupted 65 . 36%. On the other hand, 25 )lM and 50 )lM of NIIA 
resulted in an alteration of  5 3 .09% and 5 5 .04% respectively, of  the membrane 
potential .  I IIA depolarization values were 54 .34% (25 )lM) and 54 .78% (50 
)lM) .  Administration of  a base resulted in an alteration of 54 . 78%. These data 
col lectively agreed with previous findings, in which nucleoside-stimulated 
apoptosis was via mitochondria as indicated with the alterations the membrane 
and that NIA is the most effective one among them. 
6 1  
Table  2 :  Percentages of a l terat ions  o f  mitoc h o n d ri a l  membrane 
potent ia l  due to n u cleosides a d m i n istrat ion of  t h ree i n depen dent  
experime n ts, (means  ± S D, n=3) 
Compo u n d  % o f  mem b ra n e  potent ia l  
a lterat ion 
Contro l  (untreated without DMSO) 3 . 5 1 % ± 7  
25 �M of NIA 62. 1 2% ± 1 2  
5 0  �M of NIA 6 5 . 3 6% ± 9 
2 5  � M  of N I l  A 5 3 .09% ± l 3  
5 0  �M of NI l  A 5 5 .04% ± 20 
25 �M o f N II IA 54 . 34% ± 1 5  
5 0  �M of NI l IA 54 . 78% ± 6 
5 0  �M of N-base 1 54 .34% ± 1 3  
25  �M of Etoposide (positive l 7 . 1 4% ± 9  
control)  
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Fig. I V. I ? : Alteration of the m itochondrial membrane potential in H L-60 cel ls treated with various 
concentrations of nuc leos ides for 1 6  hrs. Membrane potential d isruption was detected using 
M itoCapture™ cationic dye as per manu facturer's protocol :  a) control,  b) 25 !lM N IA, c) 50 !lM NIA,  
d)  25 !lM N I TA, e) 50 11M N iTA, t) 25 11M N l I IA, g) 50 11M N I l TA, h)  50 11M N-base \ ,  i) 25 11M 
Etoposide, Representative F ACS h istogram of one of three d ifferent trials. 
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1 . 9.  e n e rat ion  of  R O  by N I A  N I I A a n d  I I I  : 
One of  the earl iest apoptotic features that is l inked to mitochondrial 
membrane potentIal disruption is the induction of Reactive Oxygen S'pecies 
(ROS) (68-70) . To investigate the in 01 ement of  ROS in the nucleosides­
mediated apoptosis, the level of ROS \ as measured by a fluorometric probe 
2 ' , 7 '  -dichlorofluoresc in diacetate (DCFH-DA) which is de-esterfied within the 
cel l - by endogenous est rases to the ionized free acid 2 ' , 7  -dichlorofluorescin. 
- ' ,7 '  -dichloro fluore cin is  then oxidized to the fluorescent 2 ' ,7 '  -
dichlorofluorescin CDCF) by hydroperoxide (a reactive Qxygen §pec ie :  ROS) .  An 
increase in RO generation was detected as early as 4 hrs ( l . 76%) by 50 11M of 
lA,  but the signifIcant induction \ as observed after 1 6  hrs ( 1 9 . 1 %) (Fig.  
IV. I 8) .  This was c learly observed \ i th the increase in shi fting of  the peak to the 
right (the over-relayed peaks in the green indicate the control [untreated 
cel lsJ) .Generation of ROS was dependent on the concentration of the 
nuc1eosides. 50 �lM of IA resulted in formation of 1 9 . 1  % of ROS.  
Interestingly, 5 0  11M of  NIIA was more effective than 5 0  11M o f  NIllA in 
generating ROS (3 . 5 6% and 0 .2 1 %  respectively) (Fig .  IV . 1 9- IV .2 1 a) .  ROS 
formation due to nucleoside treatment was synchronized with the early induction 
of apoptosis, which was c lear with the reduction in the height of one peak and 
formation of another. 
To determine whether ROS inhibition could rescue nuc leoside treated 
cel ls from apoptosis,  we preincubated the cel ls with 2, 5, 1 0mM of N-acetyl-L ­
cysteine (NAC) which is  an antioxidant. Pretreatment of  NAC prevented the 
formation of ROS and therefore decreased apoptosis part ial ly, as indicated by the 
retreat of the peaks to resemble that of the control (Fig .  IV .2 I b). Therefore, these 
64 
results indicate that ROS fomlation contributes to the abi l i ty o f  the nuc1eosides 
to induce apoptosis .  Tuc leobases were also able to generate ROS at 1 6  hrs in a 
concentration dependent manner. Although these bases seemed to be more 
effective in stimulating cel l  death scenarios, their abi l i ty was not favored 
because o f  the high necrotic rate they posses, which was c lear from the severe 
decrease in the height o f  the peak, in addition to the low solub i l i ty due to the 
absence o f  the sugar. 
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Fig. I V. I 8 : Formation of ROS in HL-60 cel ls subjected to 50 �M NlA for different periods of time. 
The level of ROS was measured by the ionization of  fluorometric probe 2 ' ,7 '  -dichlorofluorescin 
diacetae (DCFH-DA) int02 ' ,7 '  -dichlorofluoresc in (DCF) by hydroperox ide: a) control, b) 4 hrs, c) 8 
hrs, d) 1 6  hrs, e) 24 hrs, t) 1 5  �M c ispaltin (another anti-tumor agent as positive control) for 1 6hrs. 
Representat ive F ACS histogram of one of three different trials. 
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Fig. I V. 1 9: Fonnation of ROS in HL-60 cel ls treated with nuc1eosides for 1 6  ills: a) control, b) 1 2 .5  
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Fig. IV.20:  Formation of ROS in H L-60 cells treated with nucleobases for 1 6  hrs : a) 1 2 .5 �M N-base l ,  
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h istogram of one of three different trials. 
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Fig. I V.2 1 : Effect of various concentrations of the nuc leosides in the presence and absence of NAC on 
ROS formation. ROS generation was detected 16 hrs in H L-60 cells treated with nuc leosides and the 
effect of preinubation w ith N-acetyl-L-cysteine (NAC); a) ROS generation was concentration-
dependent, b) Admin istration of NAC inhibited ROS formation. Representative FACS histogram of 
one of three different trials 
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1 . 1 0 . E ffect · o f  n u cleo ide  on  t h e  ce l l  cycle d i  t ri b u t ion  of H L-60 cel l  : 
The fundamental process underlying all biological gro\vth and reproduction is 
the cell cyc le  ( l 2) . The cell cycle is  the sequence of  events whereby a l iving cel l  
dup l icates i ts nucleus and some cytoplasmic components and distributes them 
bem een daughter ce l ls  capable of carrying out the whole sequence again ( ' 2) .  It is a 
\ ery \\ e .l l  programmed phenomenon and is grossly di ided into 4 phases. These are 
1 -1 1 1 tosis phase, G , -growth phase 1 ,  S-synthesis phase, and the G2- growth phase 2 .  
In order to  assess the extent of  nucleoside-induced apoptosis  and to  investigate 
whether this process " as selective to any phase of the cel l  cycle, the ce l l  cycle 
distribution of H L-60 cel l  treated with nucleosides was studied. An accumulat ion of 
cel ls in Go-G, phase was observed (Fig .  IY.22) ,  and the increased concentration of the 
nucleosides lead to profound changes in the cel l  cycle profi les (see Fig. IV.22) .  These 
changes inc luded a decrease in the G2-M phase and S-phase populat ions 
accompanying the increase in the Go-G, population. The most interesting finding was 
that the lowest concentration of  IA (25 �M) increased the percentage of  apoptosis 
the most (20.89%), compared to 50 �M (3 .78%), whi le there was an increase in 
apoptosis induction with the highest concentrations of  N ITA, and NI I IA. Possible 
explanations for this observation are as fol lows, during this assay, samples need to be 
syringed through a 2 5 -gauge needle to prevent nuclear c lumping and to al low further 
discrimination between G "  G2 and S-phase cel ls, so that the cel ls  would not be 
mistakenly read as subdiploid ce l ls indicating apoptosis .  Another explanation could 
be that 50 �M of NIA halted the cel ls  in Go-G, phase, preventing them from 
proceeding in the ce l l  cyc le  and eventual ly the cel ls committed suicide, affecting 
several check points and regulatory proteins more than those that are affected by 
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Fig. I V.22 :  Flow cy10metric analysis of the effect of different nuc leosides concentrat ions on the 
distribution of H L-60 cel ls in the cel l  cycle by PI staining. PI-stained H L-60 cells were analyzed by 
flow cytometry after addition of different nucleosides concentration (25 11M and 50 11 M) for 1 6  hrs: a) 
control (untreated cel ls), b) 25 11M N IA, c) 50 11M NIA, d) 25 11M N I IA, e) 50 11 M  NI lA, f) 25 11 M  
N I T lA.  g) 50 11M N I I lA,  h )  25  11M Etoposide. A). Representative F A C S  h istogram o f  one o f  three 
different trials. B). Quantification of cel ls distribution in GO-G1  phase after nucleosides treatment, 
(means ± SO, n=3). 
7 1  
1 . 1 1 .  E ffec t '  o f  n u c Ieo ide on H istone Deacety l-t ransfera e s  ( H DACs), a n d  
h u m a n  b ra h ma- reIated gene 1 ( B rg l ) : 
HD Cs have been implicated in the development of cancer with the activity 
of several tumor suppressors regulated in part by H DACs (72-i6) . For example, the 
retinoblastoma tumor suppressor protein, Rb, represses transcription by recmit ing 
HDAC I (711, 7) .  The p53-dependent gene activation is  specifical ly inh ibited by HDAC l -
3 (76. 7). To address the involvement o f  chromatin modi fications in nuc leoside-induced 
apoptosi , the expres ion of HDAC I 2 ,  3 .  and Brg l were examined by Western blot 
analysis .  HDACs are a family of enzymes that catalyze the removal of acetyl group 
from post-translationally  acetylated proteins, which include his  tones, transcription 
factors, and architectural proteins (76) . The human B RG 1 (brahma-related gene 1 )  
protein is  a component of the SWIISNF fami ly  of  the ATP-dependent chromatin 
remodel ing complexes (7 ) . 
A concentrat ion-dependent decrease in the expreSSIOn of  the H DACs was 
observed upon treatment with the nucleosides (see Fig .  IV.24) .  On the other hand, a 
sl ight increase in  the expression of Brg I was detected with the increased 
concentration o f N IA, and no change with the administration o f NTIA, and NIIIA (Fig 
IV .23) .  Accordingly, these data suggest that these nuc leosides possess an anti-HDACs 
abi l i ty, and might enhance the functionali ty of c hromatin modifyi ng complexes such 
as SWIISNF. As a result ,  i nhibi tion of HDAC activity by HDAC inhibitor m ight 
increase p53 stabi l ity. p53 - induced growth arrest and apoptosis are mainly mediated 
through its transcription activity by transactivat ing or transrepressing a number of 
down-stream target genes (78) . Importantly, the DNA binding and transcriptional 
activities of p53  require a post-translat ional modification by acetylation (78). The 
72 
a ety lation of p53 ean be indue d by a variety of  p53 -aetivating agents, '..vmeh include 
agents that indu e Dl A damage and oxidative stress. 
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Fig. I V.23:  Effects of various nucleosides concentrations on the expression of HDAC- I ,  -2, -3 and 
Brg J  proteins. 40llg of nuclear cel l  extract was resolved on 1 0% SOS-PAGE and probed w ith the 
appropriate antibodies. A). Representative Western blot of one of three d ifferent trials. B). 
Quantification of H OAC- l level after nucJeosides treatment, C). Quantification of H DAC-2 level 
after nuc leosides treatment, 0). Quantification of HDAC-3 level after nuc Jeosides treatment, E). 
Quantification of Brg- I level after nuc leos ides treatment, (means ± SO, n=3). 
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2 .  Oi ' e u  i o n :  
In this study an integrated approach has been used to  examine the abi l i ty of  
synthet ic nuc leosides analogues to  induce apoptosis and to  elucidate the sequence of 
events involved in  the mechanism of nuc leoside-stimulated apoptosis. 
From the MTT ce l l  pro l i feration assay and Annex in V /PI F ACS analysis, we 
showed that three of  the four nucleosides, which were NIA NITA and NIIIA, had the 
most powerful antipro l i ferati ve effect. Interestingly, NIDA was less effective, 
probably because of the meta position of the fl uorine, which decreases its solubi l ity 
and hence renderz its uptake by the cel ls  efficient ly. In contrast, NlB has ei ther no 
effect at all or exhibited some anti-apoptotic potential . To veri fy this conflict, we 
examined i f  i t  can act as apoptosis inh ibi tor by treating the ce l ls  for 4 hrs fol lowed y 
treatment with Etoposide (a known anti-tumor agent and apoptosis inducer). We 
observed that the rate of apoptosis was abo l ished (data not shown). 
Apoptosis was detectable fol lowing 1 6  hrs exposure to 5 0  11M of NIA ITA, 
and IDA by four distinct c ri teria  (MTT pro l iferation assay, Annexin vlPr staining, 
D A fragmentation and activation o f  caspase-3 and PARP c leavage) .  Caspases, 
found in mammalian ce l l s  as inactive protease precursors, are grouped into upstream 
init iator caspases (e .g .  casapse-9) and downstream effector caspases (e.g.  caspase-3) .  
The inactive initiator caspase are first activated in response to  apoptotic stimuli and 
are responsible for processing and act ivation o f  the e ffector caspases. The activated 
effector caspases, subsequently, execute apoptosis by c leaving various cel lular 
substrates that are vital for cel l  survival (34). Western b lot analysis showed that there is  
an increase in the act ivi ty o f  caspase-3 ,  and P ARP in a concentration-dependent 
manner due to nucleosides treatment .  The act ivation of caspase-3 (effector enzyme) 
leads to the c leavage o f  P ARP, which is one o f  the essential proteins required for cel l  
74 
· 
d ' b ' l ' (63 64) • mtegnty an vIa L l ty . . PARP c1ea age prevented the repair of Dl A damage, 
b locked the depletion of  AD+ and ATP, resulting in the death of  cel ls v ia  necrosis, 
whi le  enhanc ing the ro le of Ca2+ / Mg2+ - dependent endonuc leases (55). Inactivation of 
PARP by the proteolytic activity of caspase-3 eventual ly lead to fragmentation of 
nuclear D A (a biochemical hallmark of apoptosis) ,  which can be detected by D A 
laddering assay. 
The type of apoptotic pathway taken can be deduced from the c lass of initiator 
caspase that is  activated (34), In this study, we observed that inhibition of caspase-9 
activatIon by (zLEHD-frnk) caused a reduction in or inhibition of caspase-3 
processing. On the other hand, the inhibition of caspase-B by (zIEHD-fmk) did not 
cause any change in caspase-3 activity, which indicates that these nuc1eosides-
mediated apoptosis is triggered via activation of caspase-9.  
It is  known that activation of  caspase-9 results in  the release of  Cyt c from the 
mitochondria (34,65). Indeed, we found that there was a decrease in the amount of Cyt 
c in the mitochondrial extracted from the nucleosides treated ce l ls  and an increase in 
its amount in  the cytosol ic  fraction. Thus, these compounds al lowed the release of Cyt 
c, and therefore init iated the apoptotic machinery through the m itochondrial pathway. 
The efflux of Cyt c from mitochondria to the cytosol occurred as early  as 8 hrs 
fol lowing treatment with 50 11M of NIA, NITA and NITIA, while a decrease in Bc1-2 
and Bcl-xl ,  an increase in the translocation of Bax, c leavage of B id, induction of B ak: 
and Bad, and over-expression of  p53 ,  all took place after 1 6  hrs post-treatment with 
nuc1eosides. These data indicated that there was a leakage of Cyt c, and Bax 
translocation to the mitochondria depended on the ampl ification of  caspase cascade, 
and that the induction of p53 in response to DNA degradation triggered the up-
75 
I t ' f B (40,4 1 ,4:!,66) Th £ h ' d ' regu a Ion 0 ax , ere ore, t IS Isrupted the balance between the anti-
apoptotlC heterodimer ( Bcl-2 'Ba-x) to the pro-apoptotic homodimer ( Bax !J3ax) (4:!,65), 
Our study further indicated that NlA, ITA and I DA were capable of disrupting 
mi tochondrial membran potential and causing the release of Cyt c, which 
demonstrated the direct effect of these agents on the mitochondria, Moreover, they 
caused a decrease in the expression of the anti-apoptotic protein Bel-xL. Recent 
studies have shov.;n that BcI -XL b locks the release of Cyt c (42,55,58,66) , In addition, our 
results showed that the interaction was spec ific for the large subunit of Bel -XL and not 
for the small  subunit. The large subunit is predominantly local ized into the 
mitochondrial membrane (67), 
VDAC is an abundant protein in the outer mitochondrial membrane that forms 
a large voltage-gated pore in the planar l ipid b i layer, and seems to serve in 
combination with the proapoptotic members of the Bel-2 fami ly as a pathway for Cyt 
c from the mitochondria (40,42) , However, our data demonstrated no change in the 
expression of VDAC and its regulatory protein �denine nucleotide !ranslocator 
(ANT) suggesting that the release of Cyt c might take p lace  through other gates, 
Taken together, our fi ndings supported the model that the release of Cyt c 
from the mitochondria i s  due to potential a lterations of  other pores (not VDAC and 
A1 T), enhanced by the increase in the levels of  B ax,  upregulation by p53 ,  and the 
decrease in Bel-2 and Bel-xL. Although the exact mechanism by which these 
nucleosides affected mitochondria and induced the release of Cyt c remain poorly 
formation of ROS could be one of the mechanisms that triggered the depolarization 
and alteration of mitochondrial membrane permeabi lity 
(60,6 1 ,65) , ROS induced 
mitochondrial membrane depolarization through the oxidation of certain amino 
residues in the pore voltage sensor (68-
70)
, causing alterations in membrane 
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permeabi l i t, that lead to release of apoptogenic agents from the mitochondria. 1 _ 
acetyl-L cycteme (. C ,  an antioxidant part ial ly inhibited the generation of ROS 
P artJ al ly, \ hich suggested that nuc leoside- induced apoptosis may involve factors 
other than stimulation of reactive oxygen species (ROS) .  Furthennore, we showed 
that 1 1\, IA and l IlA-mediated cell  suic ide involved chromatin alterations as 
indicated from the denaturation o f  D A 'Y ith formamide. Formamide denatures D A 
in apoptotic cel ls  but not in necrotic cel l s, or in the cel ls  with DNA breaks in the 
absence of apoptosis ( 7 1 ) .  These chromatin changes resulted from histonal degradation, 
since histones are known to stab i l ize D A against thermal modi fications (7 1 ) .  
Accordingly, these data suggested that our nucleoside-induced apoptosis might result 
in the digestion of  his tones and therefore alter DNA-histone interactions. Thus, 
chromatin condensation detected by ss-D A MAb F 7-26 triggered apoptosis as 
evidenced by the D A fragmentation (7 1 , 2 1,upregulation of p53 , , and increase in ROS 
production. 
p53 is  a D A-binding transcription factor that controls distinct programs of 
gene expression in response to D A damage and cel lular stress (72) . In response to 
various stress conditions such as DNA damage, p53 is activated to induce growth 
arrest to allow cel ls  to repair damaged DNA or apoptosis to el iminate damaged cel ls, 
if the damage is  severe and repair becomes impossible (78) . p53 i s  thus, a very broad 
sensor of many stress conditions. Under normal c irc umstances, the level of p53 is 
relatively low in the cel l .  However, i f  there is damage to the cel l ' s  DNA, this activates 
the transcription of p53 .  The process of activat ion requires changes in the 
conformation of the molecule and accumulation of p53 . Nuc leosides treatment 
resulted in the increase in the expression of p 5 3 .  It has been reported that gene 
transcription is contro l led in part by the dynamic acetylation and deacetylat ion of 
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h" 
. (75- 7) I . Istonc protems . n general, hIstone acetylation catalyzed by histone acetyl-
transferases increases gene expression by altering nucleosomal conformation and 
makIng chromatin templates accessib le by transc ription factors ( 6) \ hi le histone 
deacetylation catalyzed by HDACs reverses this process to shut do\ n gene 
expression (76) . Thus, prec ise balance between protein acetylation and deacetylation 
controls a variety of intracel lular activities involving gene expression and protein 
activation thereby playing an important ro le in cel l  growth d ifferentiation, and 
apoptosis. mce activation of p53 is enhanced by histon deacetylases (HDACs) 
(mainly HDACs - 1 ,  - �  and -3) ,  this suggested the involvement of chromatin 
modi fication in the process of cel l  death. To further investigate the role of chromatin 
modifying complexes in the cytotoxicity of these analogues we examined the 
expression of (HDACs), and observed that nuc leosides treatment (more prominent in 
the case of NIA) resulted in inhibition of HDAC 1 ,  2 and 3 expressions. Previous 
studies indicated that the aberrant transcription due to altered expression or mutation 
of genes that encode histone acetyltransferases (HATs), H DACs or their binding 
. 
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inhibitors can reactivate gene expression and inhib i t  the growth and survival of  tumor 
cel ls .  The remarkable  tumor spec ific ity of these compounds, and their potency in vitro 
and in vivo, underscore the potential of H DAC inhib i tors as exciting new agents for 
the treatment of  cancer (78). 
Another finding i s  that these nuc leosides affect the expression of Brg 1 ,  which 
is the a subunit of the human SWIlSNF (77) . SWIISNF is a large multi-subunit protein 
complex that has the general property of disrupting the structure of nucleosomes (77). 
This interesting complex exists in b iochemically distinct forms and spec ific subunits 
are required for normal development and tumor suppression (78). We have 
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d monstrated that the nucleosides analogues tested, special ly NLA.., decreased the 
expression of Brg l indicating there might be an enhanced role of S\VV F in gene 
regulation and that S WItSNF gene might be altered in this type of leukemia, 
rcpressl l1g the expression of  other genes which could be the anti-apoptotic genes 
since a decrease ll1 their expresslOn was detected earl ier. By w1derstanding how 
chromatin structure and function is normal ly modulated by diverse enzymatic 
complexes, we hope to gain insight into how these complexes are mistargeted during 
tumorgenesis .  In summary these nucleosides analogues acted as HDACs inhibitors 
through the decreasing of the expression levels of HDACs - 1 ,  -2 and -3 and indirectly 
increased the activity of HATs, therefore increasing the activation of p53 .  This in turn 
induced cel l  cycle arrest and al lowed the DNA to repair or, i f  the damage is too severe 
and can not be contained, p53 induced apoptosis to prevent further ce l l  growth. 
ucleosides also induced a concentration-dependent i nc rease in cel ls  in GO-G 1 with a 
corresponding decrease in cel ls  in S-phase of  the ce l l  cycle .  Go-G 1 i s  a crucial phase 
of ce l l  growth because the decision to begin another mi totic cyc le is made during this 
period. Occurrence of D A damage in G1 poses a part icular chal lenge, because 
repl ication of damaged D A can be deleterious and, since no s ister chromatid is  
present to provide a template for recombinational repair (80-82) . It has been proposed 
that D A damage is the exc lusive s ignal that triggers the arrest response (80-8 1 ) . We 
found that these nucIeosides caused a Go or early G1 arrest. Taken together, this 
observation, the increase expression of p53  and DNA fragmentation al lowed us to 
propose that p53 can serve as a metabo lite sensor activated by these analogues. 
Accordingly, p53 may play a role in inducing a quiescence-l ike arrest state in 
response to nutrient challenge and a senescence- l ike arrest state in response 
(apoptosis) to DNA damage. These results have important i mpl ications for the 
79 
mechanisms by which p53 pre\'ents the emergence of  genetic variants and for 
de\'eloping more effective approaches to chemotherapy based on genotype, 
It must be noted that the signal ing pathways for arrest and apoptosis, although l inked 
can function independently, because the cel l ular biomacromolecules involved in each 
pathway are di fferent . However the two pathways do have intersections and one such 
focus is the p - 3 ,  although the exact mechanism by which pS3 accumulation selects 
e i ther arr st or apoptosis is not known, The p53 pathway is probably the most 
important pathway to cel l cyc le  arrest and apoptosis, I t  is  also a major target for 
mutations in many cancers . Model ing this pathway might shed l ight on aspects of the 
pathway not commonly observed in experiments. This may lead to break throughs in 
cancer therapy by ident ifying target molecules and genes that may help manipulate 
cel l  cycles and ident ify and el iminate cancerous cel ls .  
Moreover we observed that NlA, NIIA and NIIIA had minimal effects on 
normal leukocytes and with a low necrotic rate. As for leukemic samples, these 
nucleosides were effective against lymphoblastic leukemia, especial ly acute B-cell 
leukemia  and acute T-ce l l  and not against myelogenic leukemi a. This might be 
because lymphocytes and the cel l  types such as those in the bone marrow and in the 
l ining of the intestine are normal ly rapidly dividing. Therefore, they are more 
permeable to such agents, al lowing them to exert their cytotoxic effect. also the 
carcinogenici ty of lymphoid leukemia usual ly  result from over expression pf Bcl-2 
protein which could be reversed by the activation of p53 .  On the other hand myeloid 
l eukemia arise from the presence of  Phi ladelphia chromosome, which results from a 
reciprocal translocation between chromosomes 9 and 22 ,  and their consequences can 
not be corrected by p53 activation. 
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Taken together these findings indicated that these nucleosides affected the 
prol i feratIOn of HL-60 cel l  l ine, as wel l  as certain types of leukemia through 
apoptosis indu tion, cel l  cycle arrest and chromatin modification (Fig. IV.24). 
Therefore, exhibiting a promising anticancer activity. 
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Fig. I V.24:  Proposed mechanism of action 0 t e synthetic nuc leos ides. N IA, I rA and l I lA induce 
apoptosis via m itochondrial pathway througb the activation of caspase-3 and -9, and the release of Cyt 
c., they also cause accumulation of the cel ls at the Go-G I phase of the cel l  cycle, inhib its HDACs - I ,  -2 
and -3, fac i l itating the ro le of chromatin modifying complexes (e.g. S W I/SNF) and therefore enhanc ing 
the induction of p53, which either induces cell cycle arrest and al lows the DNA to repair or induce 





\ .  Con c l u  ion(  ) a n d  reco m mend ation s :  
1 .  o n c l u  ion(  ) :  
1 uc leoside analogues are either purine analogues o r  pyrimidine analogues 
designed to inhibit  D , RNA synthesis .  In ei ther case, the structures of the drugs 
c losely resemble  their natural counterparts. There are several c lasses of synthetic 
nucleosides, one of the most important ones being the tri fluOfomethyl nucleosides. 
They are of spec ial importance becausethey exhibit a wide range of biological 
properties, inc luding anti-tumorgenic ity. In order for a drug to be considered an anti­
cancer agent it  has to be able to destroy the cancerous cel ls  and spare most normal 
cel ls  ideal ly through the mechanism of apoptosis . 
The synthetic tri fluoromethyl substituted nuc leosides investigated (exclusively 
NIA) in this study induce apoptosis in t ime and concentrat ion-dependent manners. 
This stimulation occurs via the mitochondrial pathway, as observed from the 
activation of caspase-3, c leavage of PARP and attenuation of apoptosis after 
pretreatment with caspase-3 -9 and z-V AD inhibitors. F urthermore, treatment with 
these analogues resul ted in Cyt c release in a t ime- dependent manner. Investigating 
the mechanisms of  Cyt c efflux revealed the disruption of mitochondrial membrane 
potential ,  ROS formation, decreases in Bcl-2/ Bel-XL anti-apoptotic proteins, and no 
change in Cyt c releasing gates VDAC and ANT, the later suggesting the involvement 
of other pores. In addition, these agents resulted in accumulation of the cel ls in the 
Go-G t phase of the cel l  cyc le  indicating the degradation of the DNA. Nucleosides 
also have been found to possess ant i-HDACs potenti al ,  a relatively new and exciting 
direction in cancer therapy. These data indicate that these nucleosides could be 
considered as effective anticancer agents that may lower the toxic risk of 
chemotherapeutic agents, because they are potent apoptosis inducers with low 
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necrotic rates in both normal and cancerous cel ls ,  even at concentrations as high as 
1 00 J.l 1 .  
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2 .  Reco m m en d a tion a n d  fu t u re d i rect ion : 
From the current1y known pharmacological data, i t  can be postulated that 
nucleosides possess a very high potential to retain its strong cytotoxic activity in soft 
tumors (e .g .  leukemias) and possibly, due to its di fferent cel lular uptake and the 
solubi l i ty propert ies also in multidntg resistant (MDR) tumors .  uc leosides 
analogues are taken up by tumor cel ls by a nuc leoside transporter mechanism and due 
to its l ipophi l ic  properties, their bioa ai lab i l ity is fac i l i tated by passive membrane 
d iffusion. These analogues seem to influence certain membranal transduction 
mechanisms as wel l .  Therefore, detem1ining which transporter is  involved in  their 
deli ery into the cells might be a direction for future research.  The fact that our 
nucleosides are highly cytotoxic to a leukemic ce l l  l ines and di fferent lymphoblastic 
leukemia samples through the induction of apoptosi s  al lows us to assume that other, 
unknown mechanisms of action are responsible for its excel lent cytotoxic activity. 
Testing these agents in vivo to determine the best route of administration and the 
lethal dose and therapeutic index of theses compounds might help to further j ustify 
their promising c l in ical anti-tumor activi ty. Another approach would be to investigate 
the pharmacokinetics of these nuc!eosides (how they are absorbed and metabolized 
within the body) . 
Data presented in  this thesi s  shed a l ight on the promising effects of  these 
nucleoside analogues as potential anticancer agents and open new areas of research 
i nto the design and development of better anti-cancer agents. 
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